

CURRICULUM VITAE

MITCH A. PHELPS, PH.D.

Date: July 16, 2020

Citizenship: United States

Work Address: 506 Riffe
College of Pharmacy
The Ohio State University
496 West 12th Avenue
Columbus, Ohio 43210

Work Phone: (614) 688-4370
e-mail: phelps.32@osu.edu

Home Address: 9627 Gibson Drive
Powell, Ohio 43065

Home Phone: (614) 832-2547

CURRENT POSITIONS:

Professor, Division of Pharmaceutics, College of Pharmacy and Department of Biological Chemistry and Pharmacology, College of Medicine, The Ohio State University, Columbus, Ohio

Director, Pharmacanalytical Shared Resource, Comprehensive Cancer Center
The Ohio State University, Columbus, Ohio

EDUCATION:

1988-1992: Ohio Wesleyan University, Delaware, Ohio. Physics, B.A.

1996-1999: The Ohio State University, Columbus, Ohio. Business Management/ Labor and Human Resources, M.L.H.R.

2000-2005: The Ohio State University, Columbus, Ohio. Biophysics, Ph.D.
Advisor: Dr. Peter W. Swaan
Dissertation: Novel Methods for Evaluating Riboflavin Transport and Trafficking and its Potential Role as a Target in Breast Cancer

ACADEMIC EMPLOYMENT/POSITIONS:**The Ohio State University**

- 2000-2001: Graduate Teaching Associate, Department of Physics
2001-2002: Graduate Teaching Associate, College of Medicine
2003-2005: Graduate Fellow, Biophysics Program and College of Pharmacy
2005-2006: Post-Doctoral Researcher, Comprehensive Cancer Center
2006-2008: Research Specialist/Pharmacokineticist, Comprehensive Cancer Center
2009-2014: Assistant Professor, College of Pharmacy, Division of Pharmaceutics
2009-2014: Assistant Professor, College of Medicine, Department of Pharmacology
2009-2014: Co-Director, Comprehensive Cancer Center Pharmacanalytical Shared Resource
2014-2018: Associate Professor, College of Pharmacy, Division of Pharmaceutics
2014-present: Director, Comprehensive Cancer Center Pharmacanalytical Shared Resource
2015: Interim Chair, Division of Pharmaceutics (Summer, 2015)
2016-2018: Vice Chair, Division of Pharmaceutics
2018-present: Associate Director, Clinical Pharmacology Fellowship Program
2018-present: Professor, College of Pharmacy, Division of Pharmaceutics

GRADUATE RESEARCH:

- 2002-2003: Graduate Research Associate, The Ohio State University, College of Pharmacy, Division of Pharmaceutics
Research focus: Characterize structure and function of the apical sodium-dependent bile acid transporter (ASBT)
2003-2005: Graduate Fellow, The Ohio State University, College of Pharmacy, Division of Pharmaceutics
Research focus: Characterize riboflavin transport as a potential drug target and delivery pathway in breast cancer

POST-DOCTORAL TRAINING:

- 2005-2008: Post-doctoral Researcher, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute
Research focus: Clinical and translational pharmacology of novel anti-cancer drugs and combination therapies
Mentor: Dr. James T. Dalton

INDUSTRY EMPLOYMENT/POSITIONS:**PPG Industries, Inc.**

- 1992-1993: Chemist Trainee, Delaware, Ohio. Polymer Coatings
1994-1996: Chemist II, Delaware, Ohio. Polymer Coatings
1996-1998: Chemist I, Delaware, Ohio. Polymer Coatings
1999-2000: Product Development Chemist and Group Leader, Springdale, Pennsylvania

FELLOWSHIPS AND AWARDS

- 2001: Hazel Brown Teaching Award, The Ohio State University Department of Physics
 2003: Travel Award, Council of Graduate Students, The Ohio State University
 2003-2004: Predoctoral Fellowship, American Foundation for Pharmaceutical Education

 2004: Predoctoral Fellowship, Pharmaceutical Research and Manufacturers of America (Fellowship declined due to overlap)
 2004-2005: Predoctoral Traineeship, Department of Defense Breast Cancer Research Program
 2005: Biophysics Program, Outstanding Graduate Student Award
 2009-2011: Fellow and Scholar, Center for Clinical and Translational Sciences, The Ohio State University

MENTORING and TEACHING

Doctoral Students (Dissertation Advisor)

- 2019-Pres. Alyssa M. Castillo. The Ohio State University.
 2018-Pres. Min Chen. The Ohio State University.
 2017-Pres. Donald J. Irby. The Ohio State University.
 2014-2016: Yu Kyoung Cho. Pharmacokinetics and Pharmacodynamics of Melphalan in Multiple Myeloma Patients to Predict Clinical Adverse Outcomes. The Ohio State University.
 2013-2015: Yuan Zhao. Pre-clinical and Clinical Pharmacokinetic/Pharmacodynamic Evaluations of Cyclin-Dependent Kinase Inhibitors as Chemotherapeutic Agents. The Ohio State University.
 2013-2015: Yao Jiang. Pharmacokinetic and Pharmacodynamic Studies of Lenalidomide and Pomalidomide. The Ohio State University.
 2011-2013: Lei He. The Impact of CYP3A4*22 and CYP3A5*3 on Dexamethasone and 6-Hydroxy-Dexamethasone Pharmacokinetics in Phase 1/2 Cancer Patients. The Ohio State University.
 2010-2011: Wenjun Ni. Pharmacokinetic-Pharmacodynamic and Pharmacogenetic Studies of Flavopiridol and its Glucuronide Metabolite. The Ohio State University.

Doctoral Student (Dissertation Committee Member)

- 2019-Pres. Alby Wu. The Ohio State University.
 2019-Pres. Trang Vu. The Ohio State University.
 2019-Pres. Somayya Mohamed. The Ohio State University.
 2017-2019 Sijin Guo. RNA Nanoparticle as a Safe and Effective Drug Delivery Platform for Cancer Therapy. The Ohio State University.
 2017-Pres. Zhouxiang Ji. Nano-Channel of Viral DNA Packaging Motor as Single Port to Differentiate Peptides. The Ohio State University.
 2017-Pres. Ezgi Karaesmen. The Ohio State University.
 2017-Pres. Chengxiang Zhang. The Ohio State University.
 2017-Pres. Weiyu Zhao. The Ohio State University.
 2016-2019 Pratibha Koneru. Mechanistic and Structural Investigations into the Mode of Action of Allosteric HIV-1 Integrase Inhibitors. The Ohio State University.

-
- 2016-Pres. Swagata Goswami. University of South Australia.
- 2016-2019. James Hughes. University of South Australia.
- 2016-2018 Xiao Luo. Development of Lipid-like Nanoparticles for mRNA Delivery. The Ohio State University.
- 2016-2018 Ashley Hoyte. Molecular Mechanisms for Antiviral Activities of and HIV-1 Resistance to Allosteric Integrase Inhibitors. The Ohio State University.
- 2016-2017 Yu-Chou Tseng. Application of Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-induced Cachexia. The Ohio State University.
- 2015-Pres. Sophia Liva. The Ohio State University.
- 2015-2017 Mohamed Badawi. The Ohio State University.
- 2014-2019 Anees Dauki. Targeting Androgen Receptor Signaling in Hepatocellular Carcinoma. The Ohio State University.
- 2014-2017 Yo-Ting Tsai. Dysregulation of Mitogen-Activated Protein Kinases Signaling and Immune Suppression in B-cell Leukemia. The Ohio State University.
- 2014-2017 Jilong Lee. The Ohio State University.
- 2014-2016 Dhruvit Sutaria. Investigation of Differentially Expressed Noncoding RNAs in Pancreatic Ductal Adenocarcinoma. The Ohio State University.
- 2013-2017 Shuai Dong. The Ohio State University.
- 2013-2016 Ola Elgamal. Transcriptional and post transcriptional regulation of gene expression: Applications to biology and cancer. The Ohio State University.
- 2013-2014 Bryant Yung. The Ohio State University.
- 2011-2014 Sean Harshman. Characterization of Histone H1 and Extracellular Vesicles by Mass Spectrometry. The Ohio State University.
- 2011-2013 Jonathan Sanford. The Ohio State University.
- 2011-2013 Tien-Lu Huang. Oscillating Aqueous Gels as Drug Delivery Systems. The Ohio State University.
- 2011-2013 Jocelyn Eidahl. Characterizing Interactions between the Cellular HIV-1 Integration Cofactor, LEDGF/p75 with Chromatin and HIV-1 Integrase. The Ohio State University.
- 2011-2012 Yicheng Mao. Monoclonal Antibody and Liposomal Nanoparticle-based Targeting Therapies for Chronic Lymphocytic Leukemia. The Ohio State University.
- 2011-2012 Sneha Gupta. Targeting Protein Metabolism in B-Cell Malignancies. The Ohio State University.
- 2010-2012 Chenguang Zhou. Nanocarriers for Therapeutic Nucleic Acid Delivery. The Ohio State University.
- 2010-2012 Youna Zhou. Molded Tablets for Protein Drugs. The Ohio State University.
- 2010-2012 Darlene M. Rozewski. IMiD Pharmacokinetics and Evidence of *In Vivo* Interaction with PGlycoprotein in Mice. The Ohio State University.
- 2009-2011 Georgia Triantafillou. CD74 Targeted Nanoparticles as Dexamethasone Delivery System for B lymphoid Malignancies. The Ohio State University.
- 2009-2010 Chien-Ming Li. *In vitro* and *In vivo* Pharmacology of 4-Substituted Methoxybenzoyl-Aryl-Thiazoles (SMART) and 2-Arylthiazolidine-4-Carboxylic Acid Amides (ATCAA). The Ohio State University.
- 2009-2010 Sunjoo Ahn. Novel Antimitotic Compounds with Potent *In Vitro* and *In Vivo* Antitumor Effects: The Use of Pharmacokinetics, Metabolism, Efficacy, and Toxicity Studies. The Ohio State University.
- 2009 Katie Albanese. The Ohio State University.
-

Masters Student (Advisor)

- 2014-2016 Alice Baek. Microvesicle Isolation for Use in Mouse Models of Hepatocellular Carcinoma. The Ohio State University.
2009-2012 Seungsoo Lee. The Ohio State University.

Masters Student (Examination and/or Thesis Committee Member)

- 2012-2014 Di Bei. The Ohio State University.
2011-2012 Miranda McClain. The Ohio State University.
2010-2011 Naveen Kanthamneni. The Ohio State University.
2010-2011 Jennifer Dulin, DVM. Influence of Exercise on the Distribution of 99mTechnetium-Methylene Diphosphonate Following Intra-articular Injection in Horses. The Ohio State University.

Professional/PharmD (Research Advisor)

- 2018 – 2019 Yizhen Guo. The Ohio State University.
2014 Yoonji Lee. The Ohio State University.
2013-2015 Joanne Jih. The Ohio State University.
2013-2014 Mikhil Adusumilli. The Ohio State University.
2012 Kriss Petrovskis. The Ohio State University.
2011-2012 Diana Chung. The Ohio State University.
2010-2013 Elizabeth Marek. The Ohio State University.
2008-2009 Nicholas Treadway. The Ohio State University.

Undergraduate (Senior Honors Advisor)

- 2013 Olesya Rabosyuk. The Ohio State University.
2012-2013 Divya Subramanian. The Ohio State University.
2012 Zhe Li. The Ohio State University.
2011-2013 Christopher Waker. The Ohio State University.
2010-2011 Stephen Rasiah. The Ohio State University.
2010-2011 Bethany Cunningham. The Ohio State University.

Undergraduate (Research Advisor)

- 2014 Manuella de Carvalho Capparelli. The Ohio State University.
2014 Kyle Barth. The Ohio State University.
2011 Tyler Thompson. The Ohio State University.
2009-2010 Michael Enzerra. The Ohio State University.

Clinical Fellows (Co-Advisor)

- 2010-2012 Ming Poi. The Ohio State University.
2010-2012 Joseph Kitzmiller. The Ohio State University.

Post-Doctoral Researchers (Advisor)

- 2017-2019 Mohamed Badawi. The Ohio State University.
2015-2016 Yantong Sun. The Ohio State University.
2012-2014 Darlene Rozewski (Bystry). The Ohio State University.
2012-2014 Yue Gao. The Ohio State University.
2009-2011 Xiaoxia Yang. The Ohio State University.
2009-2011 Jia Ji. The Ohio State University.
-

Teaching, The Ohio State University

- 2000-2001: Introductory Physics (Physics 111 and 112), Department of Physics, Graduate Teaching Associate
- 2002: Biomedical Informatics (IBGP 705), College of Medicine, Integrated Biomedical Sciences Graduate Program, Graduate Teaching Associate
- 2007: Advanced Pharmacokinetics (Pharmacy 802), College of Pharmacy, Division of Pharmaceutics, Instructor
- 2010-2014: Advanced Pharmacokinetics (Pharmacy 802/8020), College of Pharmacy, Division of Pharmaceutics, Instructor/Course Director
- 2010-2015: Drug Discovery and Development (Pharmacy 425/4320), College of Pharmacy, Division of Pharmaceutics, Instructor/Course Director
- 2013-2016: Laboratory and Diagnostic Testing (Pharmacy 6260), College of Pharmacy, Division of Pharmaceutics, Instructor/Course Director
- 2013-present: Pharmacometrics (Pharmacy 8025), College of Pharmacy, Division of Pharmaceutics, Instructor/Course Director
- 2015-present: Applied Pharmacokinetics and Pharmacodynamics (Pharmacy 7584), College of Pharmacy, Division of Pharmaceutics, Instructor/Course Director
- 2016-present: Fundamentals of Drug Disposition (Pharmacy 8005), College of Pharmacy, Division of Pharmaceutics, Instructor

PROFESSIONAL AFFILIATIONS AND SERVICE**Professional Organizations**

- 2019-present: Member, American Society of Clinical Oncology (ASCO)
- 2016-present: Faculty Advisor, American Association of Pharmaceutical Scientists (AAPS) Student Chapter, The Ohio State University
- 2014-present: Member, International Society of Pharmacometrics (ISoP)
- 2014-2018: Member, International Society of Extracellular Vesicles (ISEV)
- 2011-present: Member, American Society of Clinical Pharmacology and Therapeutics
- 2010-present: Member, American College of Clinical Pharmacology (ACCP)
- 2010-present: Member, American Society of Hematology (ASH)
- 2009-2017: Member, American Association for Cancer Research (AACR)
- 2001-present: Member, American Association of Pharmaceutical Scientists (AAPS)
- 2000-2005: Member, Biophysical Society
- 2005-2007: Chair, Abstract Review Committee, Biotechnology Conference (June, 2006), AAPS, Pharmaceutics and Drug Delivery (PDD) Section
- 2005-2006: Editorial Board Member, AAPS, PDD News Letter
- 2004-2007: Co-Chair and Member, Website Design Committee, AAPS, PDD

Editorial and Review Service

- 2008-present: Journal of Chromatography B, Ad Hoc Reviewer
- 2009-present: Hematology Research and Reviews, Ad Hoc Reviewer
- 2010-present: Current Medicinal Chemistry, Ad Hoc Reviewer
- 2010-present: Journal of Pharmaceutical and Biomedical Analysis, Ad Hoc Reviewer
- 2010-present: Journal of Pharmacology and Experimental Therapeutics, Ad Hoc Reviewer
- 2011-present : Bioorganic and Medicinal Chemistry Letters, Ad Hoc Reviewer
- 2011-present : Journal of Clinical Pharmacology, Ad Hoc Reviewer

2011-present : Clinical Cancer Research, Ad Hoc Reviewer
 2012-present : Clinical Pharmacology and Therapeutics, Ad Hoc Reviewer
 2013-2014: Guest Editor, Clinical Pharmacology and Therapeutics special issue in Oncology
 2015-present: Blood, Ad Hoc Reviewer
 2015-present: Cancer Research, Ad Hoc Reviewer
 2015-present: Chemical Research in Toxicology, Ad Hoc Reviewer
 2016-present: Clinical Pharmacokinetics, Ad Hoc Reviewer
 2016-present: Expert Review of Clinical Pharmacology, Ad Hoc Reviewer
 2016-present: Pharmacogenomics Journal, Ad Hoc Reviewer
 2017-2018: Current Pharmacogenomics & Personalized Medicine, Editorial Board
 2017-Present: Clinical and Translational Science, Ad Hoc Reviewer
 2017-2018: Current Cancer Therapy Reviews, Editorial Board
 2018-present: Antimicrobial Agents and Chemotherapy, Ad Hoc Reviewer
 2018-present: Xenobiotica, Ad Hoc Reviewer
 2018-2019: Annals of Clinical Pharmacology and Toxicology, Editorial Board
 2019-present: International Journal of Molecular Sciences, Ad Hoc Reviewer
 2019-present: Cancer Chemotherapy and Pharmacology, Ad Hoc Reviewer
 2019-present: AAPS Journal, Ad Hoc Reviewer

Grant Review Service

2017, March 30 Grant Reviewer: Dutch Organisation for Health Research and Development (ZonMw), Rational Pharmacotherapy Program
 2018, April 16-17 Grant Reviewer: NICHD U54 Contraception Centers ad-hoc review panel
 2018, December 7 Grant Reviewer and Chair: NIAID Special Emphasis Panel, ZAI1-JBS-A-J1 PAR-18-632
 2019, April 29-30 Grant Reviewer: NICHD U54 Contraception Centers ad-hoc review panel
 2019, October 4 Grant Reviewer: 2020/01 ZCA1 SRB-A (J1) S SEP-2: Small Grants Program for Cancer Research (Omnibus R03)
 2020, February 6-7 Grant Reviewer: NCI ZCA1 SRB-5 (M1) NCI Program Project (P01)

Institutional Service

2009-present: Preceptor/Mentor, Clinical Pharmacology Fellowship Program, Department of Pharmacology, College of Medicine
 2009-2011: Member, Doctor of Pharmacy (PharmD) Professional Program Admissions Committee, The Ohio State University College of Pharmacy
 2010-2013: Preceptor/Mentor, Clinical Oncology PharmD Fellowship Program, Department of Pharmacy Practice, College of Pharmacy and Division of Pharmacy, University Medical Center
 2010-2014: Alternate Reviewer, Institutional Animal Care and Use Committee
 2010-2014: Member, Bachelor of Pharmaceutical Sciences (BSPS) Program Curriculum Committee, The Ohio State University College of Pharmacy
 2011-present: Grant Reviewer, Various review panels within the Comprehensive Cancer Center, College of Pharmacy, and Center for Clinical and Translational Science
 2013-2014: Chair, Technology and Education Resources Committee, The Ohio State University College of Pharmacy

2014-2015:	Chair, Committee on Committees, The Ohio State University College of Pharmacy
2014-2018:	Member, Graduate and Research Committee, The Ohio State University College of Pharmacy
2016-2018:	Chair, Pharmaceutics Graduate Program Committee
2018-2019:	Member and Chair, Research Program Task Force
2018-present:	Chair, Faculty Search Committee, PK/PD in Infectious Diseases, The Ohio State University College of Pharmacy
2018-2020:	Chair, Faculty Search Committee, Discovery Themes/ The Ohio State University College of Pharmacy
2019-present:	Member, Research Program Committee, The Ohio State University College of Pharmacy

RESEARCH

Current Funding

- 04/01/2020 - 03/31/2026. *The Chesapeake-Ohio Pharmacokinetics Core for the ETCTN*. National Institute of Health/National Cancer Institute. U24CA247648. **Role: Co-I** (MPIs: Rudek and Baker). Goal: This project will provide pharmacology expertise to support development and conduct of pharmacokinetic/pharmacodynamic studies in early phase clinical trials within the NCI Experimental Therapeutics Clinical Trials Network (ETCTN).
- 12/01/2011 - 11/30/2024. *Discovery of anticancer agents of diverse natural origin*. National Institute of Health. P01 CA125066. **Role: Co-I (Core 2)** (PI: Kinghorn). Goal: The focus and goal of this application is to identify and characterize chemical products from natural plant origin as potential anti-cancer agents.
- 09/24/2017 - 04/30/2022. *Translational Candidate-gene Studies of Simvastatin-induced Myopathy in African Americans*. National Institute on Minority Health and Health Disparities/National Institute of Health. R01MD011307. **Role: Co-I** (PI: Smith). Goal: This project compares daily simvastatin systemic exposure in African American CYP3A4*22 carriers and non-carriers, providing better quantification of the increased simvastatin exposure of muscle and better estimation of the resulting increase in risk of simvastatin myopathy.
- 08/01/2016 - 07/31/2021. *Overcoming IMiD resistance in Myeloma*. National Cancer Institute/National Institute of Health. R01CA201382. **Role: MPI** (MPIs: Phelps, Hofmeister, Pichiorri). Goal: This project evaluates the mechanisms of IMiD resistance in multiple myeloma and evaluate the ability of AR-42 to overcome resistance in a phase 1/2 clinical trial.
- 08/01/2019 - 07/31/2021. *Diversity Supplement--A. Castillo: Overcoming IMiD resistance in myeloma*. National Cancer Institute. R01CA201382 (Supplement) **Role: MPI** (Pichiorri/Hofmeister/Phelps). Goal: The proposed studies will investigate the mechanisms of IMiD-induced resistance by assessing: (a) the functional role of CD44 in IMiD cellular uptake; (b) the role of small-non-coding-RNA (miRNA) in regulating CRBN and IRF4 and their significance in IMiD treatment; (c) if resistance can be overcome by combining AR-42 with an IMiD in a Phase 1 clinical trial.
- 01/01/2020 – 12/31/2021. Development of LNA gapmers anti-HOXB-AS3 to treat Acute Myeloid Leukemia. OSU Comprehensive Cancer Center. **Role: MPI** (Garzon and Phelps).

- Goal: To develop oligonucleotide therapies to target HOXB-AS3, a long, non-coding RNA with elevated expression in cytogenetically normal AML.
- 09/12/1997 - 11/30/2025. *OSU Comprehensive Cancer Center Support Grant: Pharmacanalytical Shared Resource*. National Cancer Institute 5 P30CA016058-36. **Role: Co-I** (PI: Pollock). Goal: To support the programs, services, research, and administration of the OSU Comprehensive Cancer Center.
 - 09/01/2015 - 08/31/2020 (NCE). *Phosphatase activation as therapeutic strategy for Chronic Lymphocytic Leukemia*. National Institute of Health/National Cancer Institute. R01CA197844-01. **Role: MPI** (MPIs: Phelps and Muthusamy). Goal: This project focuses on development of a novel phosphatase inhibitor, OSU-2S, and an accompanying novel immunoliposomal formulation to selectively target ROR1-expressing B-cells in chronic lymphocytic leukemia.

Prior Funding

- 12/03/2015 - 11/30/2020. *Biologic and therapeutic significance of miR-155 in AML*. National Cancer Institute. R01CA201184. **Role: Co-I** (PI: Marcucci/Croce/Garzon). Goal: The majority of AML patients die of their disease when treated with currently available treatments, therefore the need for the development novel treatments is evident. One of the processes contributing to AML is the abnormal expression in leukemia cells of microRNAs, short RNA molecules that regulate the expression of "key" proteins in normal cells. The overarching goal is to understand how the deregulated expression of one of these microRNAs, miR-155, contributes to the development of leukemia and how it can be targeted to eliminate the disease by: a. creating AML mice with abnormally high levels of miR-155; b. using them as a model to develop a novel anti-miR-155 compound (LNA-antimiR-155) not yet in the clinic; c. conducting a clinical trial in AML patients with an emerging drug (MLN4924) that has been already tested in human and that we have shown able to decrease very efficiently the expression of miR-155 in leukemia cells.
- 04/21/2015 - 03/31/2020. *Dual targeting of XPO1 and BTK in B cell malignancies*. National Cancer Institute/National Institute of Health. 5R01CA192928-05. **Role: Co-I** (PI: Lapalombella). Goal: This project aims to improve our understanding of the role of XPO1 in the context of oncogenic signaling important for the pathogenesis and microenvironment homing of CLL, and proposes a Phase I trial of ibrutinib and selinexor combination therapy.
- 03/1/2014-02/29/2020. *Phase I trials of anti-cancer agents*. National Cancer Institute. UM1 CA186712. **Role: Co-I** (Carson). Goal: This project uses correlative studies to evaluate clinical outcomes in the context of basic science observations. The major goal of this project is to investigate Phase I agents to obtain maximum tolerated dose and to perform clinical pharmacokinetics of these agents.
- 12/01/2012-11/30/2019. *Discovery of anticancer agents of diverse natural origin*. National Institute of Health. P01 CA125066. **Role: Co-I** (PI: Kinghorn). Goal: The focus and goal of this application is to identify and characterize chemical products from natural plant origin as potential anti-cancer agents.
- 07/01/2017-06/30/2019. *A preventive pharmacotherapy for neonatal abstinence syndrome*. National Institute of Child Health and Human Development. R21HD092011. **Role: Co-I** (PI: Oberdick). Goal: The goal of this project is to develop a drug therapy that can prevent opioid dependence in utero in order to suppress or reduce neonatal withdrawal (neonatal abstinence syndrome).

6. 07/01/2013-6/30/2019. *Targeted delivery of microRNA-loaded microvesicles for cancer therapy*. National Institute of Health. 1UH2TR000914-01. **Role: MPI** (MPIs: Phelps and Schmittgen). Goal: This proposal will develop a microvesicle drug delivery system to target therapeutic miRNAs to hepatocellular carcinoma cells and tumors. A unique feature of this system is that the nucleic acid cargo is synthesized by the cells that produce the microvesicles, thus alleviating the need for synthetic oligonucleotides.
7. 09/26/2013-04/30/2019. *The Ohio State University Center for Clinical and Translational Science*. National Center for Advancing Translational Sciences/National Institute of Health. UL1TR001070. **Role: Co-I** (PI: Jackson). Goal: The goals of this Center will continue to focus on integrating the traditional biomedical research process (basic scientific discovery with translation to the bedside to dissemination into the community for improved patient outcomes) with a public health model (surveillance to prevention to response).
8. 04/01/2012-03/31/2017. *Targeting the Aberrant Kinome-Epigenome in AML*. National Cancer Institute. 5R01CA158350-03. **Role: Co-I** (PI: Garzon). Goal: To target leukemia mechanisms by increasing miR-29b expression via novel therapeutic approaches.
9. 07/01/2013 - 06/30/2016. *Targeted delivery of microRNA-loaded microvesicles for cancer therapy*. National Institute of Health. UH2TR000914. **Role: MPI** (MPIs: Schmittgen and Phelps).
10. 01/2013-12/2015. *Optimizing selective in vivo inhibition of pancreatic tumor JAK2/STAT3 signaling*. National Cancer Institute. R21 CA173473-01 (\$425,963 total 2-year award). **Role: PI (Phelps)**. Goal: To optimize the dosing regimen of a novel, water soluble STAT-3 inhibitor, FLLL-100P, using modeling and simulation through thorough characterization of its pharmacokinetic and pharmacodynamic properties in a mouse model of pancreatic cancer.
11. 10/01/2010-09/30/2015. *SCOR: Experimental therapeutics in CLL*. Leukemia & Lymphoma Society. LLS 7004-11. **Role: Co-I** (PI: Byrd). Project 1: Pre-Clinical and Clinical studies of Flavopiridol in CLL; Project 3: Therapeutic Targeting of Novel Kinases in CLL. Goal: The central theme of this proposal is the pursuit of pre-clinical and clinical investigations of multi-targeted therapies for the treatment of genetically high risk CLL.
12. 04/01/2010-03/31/2015. *Expression Genetics in Drug Therapy*. National Institute of General Medical Sciences. U01 GM092655 (\$11,010,785 total 5-year award). **Role: Co-I**. (PI: Sadee). Goal: The goal of this project was to identify the polymorphic genetic factors that contribute to variable gene expression in drug targets, transporters, and metabolic enzymes relevant for current drug therapy and disease.
13. 03/2014-02/2015. *Quantitative Pharmacology Data Generation with TG02*. Tragara Pharmaceuticals. GRT00034112 (\$51,380 total 1-year award). **Role: PI (Phelps)**. Goal: To evaluate protein binding and other potential factors that contribute to inter-subject variability in pharmacokinetics of TG02, an orally bioavailable cyclin dependent kinase inhibitor.
14. 08/01/2010-07/31/2014. *Experimental Therapeutics in Leukemia SPORE*. National Cancer Institute. P50CA140158 (\$9,200,000 total 5-year award). **Role: Co-I**. Goal: To develop therapies for treatment of leukemia.
15. 08/01/2010-07/31/2012. *Development of novel compounds to inhibit PRMT5 enzyme in high grade astrocytomas*. NINDS. R21NS071346 (\$187,501). **Role: Co-I** (PI: Baiocchi). Goal: To develop small molecule inhibitors of PRMT5 and evaluate their activity, pharmacokinetics and efficacy in *in vitro* and mouse models.
16. 07/01/2009-06/30/2012. *Biologic activity of the curcumin analog FLLL32 against canine osteosarcoma*. Morris Animal Fdn. D09CA-500 (\$290,120). **Role: Co-I**. (PI: London). Goal: To develop selective and potent curcumin analogs to inhibit JAK2/STAT3 signaling in canine osteosarcoma.

17. 07/15/2008-06/30/2012. *Modulating the tumor micro-environment in CLL using flavopiridol and lenalidomide*. NCI. R21 CA133875 (\$675,000). **Role: Co-I**. Goal: To evaluate pharmacokinetics and pharmacodynamics of combined flavopiridol and lenalidomide in patients with CLL.
18. 03/01/2010-02/29/2012. *Evaluating the anti-tumor effects of novel curcumin analogs in melanoma*. National Cancer Institute. Research Grant R21 CA141434 (\$359,882.00). **Role: Co-I**. Goal: To develop potent and selective JAK2/STAT3 inhibitors and evaluate their *in vivo* pharmacokinetics and efficacy.
19. 01/2010-12/2011. *Pharmacogenetics in early phase clinical trials: flavopiridol as a model*. The Ohio State University. National Center for Research Resources, OSU Center for Clinical and Translational Science. K12 Mentored Research Grant/Career Development Award 5 KL2 RR025754 (\$200,000). **Role: PI (Phelps)**. Goal: To evaluate the influence of pharmacogenetic factors in flavopiridol disposition and outcomes in patients with CLL.
20. 10/2/2008-10/1/2011. *Phase I study of bendamustine and fractionated stereotactic radiotherapy for patients with 1- 3 brain metastases from solid malignancies*. NCCN. Research Grant GRT00014970 (\$200,000). **Role: Co-I**. Goal: To determine safety of this combined regimen and evaluate bendamustine pharmacokinetics and distribution into metastatic brain lesions in this patient population.
21. 07/01/2009-06/30/2011. *Dual inhibitors target JAK2 and STAT3 as a novel therapeutic approach for pancreatic cancer*. Research Institute at Nationwide Children's Hospital. Research Grant/Contract GRT00014236 (\$99,000.00). **Role: Co-I**. Goal: Evaluate novel JAK2 and STAT3 inhibitors in *in vitro* and *in vivo* models of pancreatic cancer.

Clinical Studies

1. 2020-present. A pilot study of blood-based biomarkers for response to immune checkpoint inhibitors. PI: Owen D. Co-I: **Phelps MA**. Columbus, Ohio. OSU20001.
2. 2018-present. A Phase I Study of Neoadjuvant Chemotherapy with the Gamma Secretase Inhibitor R04929097 in Combination with Paclitaxel and Carboplatin in Patients with Clinical Stage II-III Negative Breast Cancer. PI: Wesolowski R Co-I: **Phelps MA**. Columbus, Ohio. 2018C0013, OSU10011 (re-open).
3. 2016-present. Phase I Evaluation of Lenvatinib and Weekly Paclitaxel in Patients with Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. PI: Backes F Co-I: **Phelps MA**. Columbus, Ohio. 2016C0009
4. 2015-present. A Phase 1b Trial of AR-42 with Pomalidomide in Relapsed Multiple Myeloma. PI: Efebera Y Co-I: **Phelps MA**. Columbus, Ohio. 2015W0166, OSU15004.
5. 2014-present. A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma. PI: Woyach J Co-I: **Phelps MA**. Columbus, Ohio. 2014CO180, OSU14087.
6. 2013-present. Omega-3 Fatty Acids and ERPR(-) and HER-2/NEU(+) Breast Cancer Prevention. PI: Clinton S Key Personnel: **Phelps MA**. Columbus, Ohio. 2013CO668.
7. 2013-present. A dose escalation study of ibrutinib with lenalidomide for relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. PI: Byrd JC; Co-Is and Key Personnel: Andritsos LA, Jones JA, Flynn JM, Maddocks KJ, **Phelps MA**, Johnson AJ, Stefanos MN, Lollini AL, Hutchinson TL, Khountham S, Casterline TS. 2013C0019, OSU13018.

8. 2012-present. A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia. PI: Rogers K Co-I: **Phelps MA**. Columbus, Ohio. 2012CO139, OSU12200.
9. 2012-present. A Randomized Phase 2 Study of Single Agent GSK2118436 (BRAFI) vs. Combination Regimen GSK2118436 (BRAFI) and GSK1120212 (MEKI) in Patients with BRAF Mutation or BRAF Gene Fusion Defect in Thyroid Carcinoma. PI: Shah M; Co-I: **Phelps MA**. 2012C0074, OSU12064.
10. 2011-present. Phase 1B/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL. PI: Rogers K Co-I: **Phelps MA**. Columbus, Ohio. 2011CO115, OSU11120.
11. 2011-present. Genetic Influences on Statin Concentrations in Adult African Americans. PI: Smith S; Co-Is and Key Personnel: Cirpili EM, **Phelps MA**, Sadee W, Blais DM, Siegel C, McDavid AD, Jackson RD, Satiani B, Hartman KLS, Luzum JA. 2011H0402.
12. 2011-present. Phase II study of lenalidomide to repair immune synapse response and humoral immunity in early-stage, asymptomatic chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with high-risk genomic features. PI: Byrd JC; Co-Is and Key Personnel: Jaglowski SM, Lucas MS, Byrd JC, Moran ME, Christian BA, Blum KA, Woyach JA, Awan FT, Andritsos LA, Flynn JM, Maddocks KJ, **Phelps MA**, Johnson AJ, Muthusamy N, Lollini AL, Quinter AR, Hutchinson TL, Khountham S, Geyer SM, Casterline TS, Canning RL, Brookfield CD, Jianfar M. 2011C0005, OSU10156, NCI8834.
13. 2010-present. Buckeye Surveillance, Contact, and Research for MGUS, Myeloma and Amyloidosis. PI: Rosko A Co-I: **Phelps MA**. Columbus, Ohio. 2010CO126.
14. 2008-2017. A Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy for Patients with 1- 4 Brain Metastases from Solid Malignancies. PI: Grecula JC Co-I: **Phelps MA**, Kendra KL, Chiocca EA, Olencki TE, Mayr NA, Cavaliere R, Ammirati M, McGregor JM, Mrozek E, Lautenschlaeger T, Abdel Karim NF, Wei L, Mayer LM, Mathur V. NCCN. Columbus, Ohio. 2008C0133, OSU08142.
15. 2014-end date. Increasing adherence to adjuvant hormonal therapy among breast cancer patients: phase 2 - pilot test of intervention for feasibility. PI: DM Post; Co-Is and Key Personnel: Pasket ED, Lustberg MB, Shapiro CL, Wesolowski R, **Phelps MA**, Ramaswamy B, Jena A, Young GS, Aker HA, Layman RM, Macrae ER, Mrozek E, Lyons BL, Goodwin JL, Walunis JM, Krok JL. 20014C0006.
16. 2012-end date. A Phase I Trial of GSK2118436 (BRAFI) and Pazopanib in Patients with BRAF-Mutated Advanced Malignant Tumors. PI: Shah, M; Co-Is: Timmers, CD, **Phelps MA**, Schaaf, LJ, Poi MJ, Spiros, JA. Columbus, Ohio. 2012C0078, OSU12066.
17. 2012-2015. A Prospective Double-Blinded, Observational Clinical Cohort Study of the Association Between Tacrolimus Exposure and CYP3A4, CYP3A5 Genotypes in Adult Hematopoietic Stem Cell Transplant Recipients. MPIs: **Phelps MA** and Poi MJ; Co-Is: Wang D, Sadee W, Devine SM, Duda JE, Roddy JVF, Khan A, Kang YR. Columbus, Ohio. 2012C0021, OSU12002.
18. 2011-2015. Multicenter, phase 2 study of Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in relapsed or refractory mantle cell lymphoma. Co-I: Blum K, Andritsos L, Baiocchi R, Byrd JC, Christian B, Flynn J, Jaglowski S, Jones JA, **Phelps MA**, Porcu P. Pharmacyclics, Inc. Clinical Trial. Columbus, Ohio. PCYC-1104-CA, 2011W0039, OSU10155. Summary: This is a proof-of-concept, Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of PCI-32765 in subjects with relapsed/refractory MCL.
19. 2011-2015. A randomized study to compare the effect of short- and long-term schedules of cryotherapy on the incidence and severity of mucositis in high-dose melphalan. PI:

- Hofmeister, CC; Co-Is and Key Personnel: Benson SM, Tackett KA, Devine, SM, Lamprecht MS, Lester JL, Efebera YA, **Phelps MA**, Hummel HL, Meheran KM, Gill JS, Duda JE. 2011C0080.
20. 2011-2014. A Multi-Institutional Phase II Study of the Akt inhibitor MK-2206 in Refractory Biliary Cancers. Co-I: Bekaii-Saab T, Rose J, Bloomston M, Schmidt C, Muscarella P, **Phelps M**, Liu Z, El-Rayes B, O'Neil B, El-Khoueiry A, Javle M. NCI. Columbus, Ohio. NCI8735, OSU10104.
 21. 2011-2014. A phase 1, dose-escalation trial of rituximab and bendamustine in combination with Bruton's tyrosine kinase inhibitor, PCI-32765, in patients with relapsed diffuse large B-cell lymphoma, mantle cell lymphoma, or indolent non-Hodgkins lymphoma. Co-I: Blum KA, Jaglowski JM, **Phelps MA**, Byrd JC, Christian BA, Andritsos LA, Jones JA, Flynn JM, Penza SL, Baiocchi RA, Porcu P, Maddocks-Christianson KJ, Wei L. NCI. Columbus, Ohio. 2011C0091, OSU10052.
 22. 2010-2014. A phase 1 dose-escalation study of ABT-888 in combination with carboplatin in HER2 negative metastatic breast cancer. Co-I: Ramaswamy B, **Phelps MA**, Knopp M, Hall N, Lustberg MB, Layman RM, Grever MR, Hicks WJ, Rupert RD, Ghany AM, Shapiro CL, Villalona MA, Mrozek E, Wesolowski R. NCI. Columbus, Ohio. 2010C0070, OSU10080.
 23. 2010-2013. A phase 1 study of neoadjuvant chemotherapy with the gamma secretase inhibitor RO4929097 in combination with paclitaxel and carboplatin in patients with clinical stage II-III triple negative breast cancer. Co-I: Mrozek E, **Phelps MA**, Ramaswamy B, Liu Z, Schaaf LJ, Weiss R, Layman RM, Hicks WJ, Rupert RD, Ghany AM, CL Shapiro, Li X, Starrett S, Ottman S. NCI. Columbus, Ohio. 2010C0043, OSU10011.
 24. 2010-2013. A phase 1/2 study of rituximab, bendamustine, and obatoclox in patients with relapsed or refractory indolent non-Hodgkins lymphoma. Co-I: Christian BA, **Phelps MA**, Byrd JC, Blum KA, Benson DM, Devine SM, Hofmeister CC, Andritsos LA, Jones JA, Flynn JM, Grever MR, Baiocchi RA, Porcu P. NCI. Columbus, Ohio. 2010C0056, OSU10040.
 25. 2009-2014. A phase 1/2 study of veltuzumab (IMMU-106, HA20), a humanized anti-CD20 monoclonal antibody, combined with milatuzumab (IMMU-115, HLL1), a humanized anti-CD74 monoclonal antibody, in relapsed and refractory B-cell non-Hodgkins lymphoma. Co-I: Christian BA, **Phelps MA**, Byrd JC, Lozanski G, Benson DM, Devine SM, Andritsos LA, Jones JA, Flynn JM, Muthusamy N, Baiocchi RA, Porcu P, Jansak BS. Immunomedics, Inc. Columbus, Ohio. 2009C0064, OSU09024.
 26. 2009-2011. Evaluation of the influence of the CYP3A4 rs35599367 polymorphism on outcomes of tamoxifen therapy. PI: **Phelps MA**, Lustberg M, Wang D, Pilarski R, Geyer S, Shapiro CL, Sadee W. Columbus, Ohio. 2010C0030, OSU09137.

Publications

The full list of publications can be accessed at

<https://www.ncbi.nlm.nih.gov/myncbi/mitch.phelps.1/bibliography/public/>

1. Zhang EY, **Phelps MA**, Cheng C, Ekins S, Swaan PW. *Modeling of active transport systems*. Adv Drug Deliv Rev. 2002 March 31; **54**(3):329-54. PMID: 11922951.
2. **Phelps MA**, Foraker AB, Swaan PW. *Cytoskeletal motors and cargo in membrane trafficking: opportunities for high specificity in drug intervention*. Drug Discov Today. 2003 June 1; **8**(11):494-502. PMID: 12818519.

3. Huang SN, **Phelps MA**, Swaan PW. *Involvement of endocytic organelles in the subcellular trafficking and localization of riboflavin*. J Pharmacol Exp Ther. 2003 Aug 30;6(2):681-7. Epub 2003 Apr 29. doi: 10.1124/jpet.103.051581. PMID: 12721324.
4. Wu Z, Gao W, **Phelps MA**, Wu D, Miller DD, Dalton JT. *Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry*. Anal Chem. 2004 Feb 1;76(3):839-47. doi: 10.1021/ac0351670. PMID: 14750883. PMCID: PMC2104782.
5. **Phelps MA**, Foraker AB, Gao W, Dalton JT, Swaan PW. *A novel rhodamine-riboflavin conjugate probe exhibits distinct fluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization studies*. Mol Pharm. 2004 Jul-Aug;1(4):257-66. PMID: 15981585.
6. Zhang EY, **Phelps MA**, Banerje A, Khantwal CM, Chang C, Helsper F, Swaan PW. *Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2)*. Biochemistry. 2004 Sep 14;43(36):11380-92. doi: 10.1021/bi049270a. PMID: 15350125.
7. Gao W, Reiser PJ, Coss CC, **Phelps MA**, Kearbey JD, Miller DD, Dalton JT. *Selective androgen receptor modulator (SARM) treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats*. Endocrinology. 2005 Nov;146(11):4887-97. Epub 2005 Aug 11. doi: 10.1210/en.2005-0572. PMID: 16099859. PMCID: PMC2039881.
8. Mason CW, D'Souza VM, Bareford LM, **Phelps MA**, Ray A, Swaan PW. *Recognition, co-internalization, and recycling of an avian riboflavin carrier protein in human placental trophoblasts*. J Pharmacol Exp Ther. 2006 May;317(2):465-72. Epub 2006 Jan 6. doi: 10.1124/jpet.105.096149. PMID: 16399883.
9. George TG, Johnsamual J, Delfin DA, Yakovich A, Mukherjee M, **Phelps MA**, Dalton JT, Sackett DL, Kaiser M, Brun R, Werbovetz KA. *Antikinetoplastid antimetabolic activity and metabolic stability of dinitroaniline sulfonamides and benzamides*. Bioorg Med Chem. 2006 Aug 15;14(16):5699-710. Epub 2006 May 3. doi: 10.1016/j.bmc.2006.04.017. PMID: 16675220.
10. Byrd JC, Lin TS, Dalton JT, Wu D, **Phelps MA**, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. *Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high risk chronic lymphocytic leukemia*. Blood. 2007 Jan 15;109(2):399-404. Epub 2006 Sep 26. doi: 10.1182/blood-2006-05-020735. PMID: 17003373. PMCID: PMC1785084.
11. Christian BA, Fischer B, Blum KA, Brooker-McEldowney M, Moran ME, Andritsos LA, **Phelps MA**, Dalton JT, Colevas AD, Byrd JC, Grever MR, Lin TS. *Flavopiridol in Chronic Lymphocytic Leukemia*. Clinical Leukemia. 2007 Sep;1(5):292-7.
12. **Phelps MA**, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, Lin TS, Grever MR, Dalton JT. *Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule*. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jun 1;868(1-2):110-5. Epub 2008 Apr 22. doi: 10.1016/j.jchromb.2008.04.023. PMID: 18490204. PMCID: PMC2504738.
13. Johnston JS, **Phelps MA**, Blum KA, Blum W, Farely KL, Dalton JT. *Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma*. J Chromatogr B Analyt Technol

- Biomed Life Sci. 2008 Aug 1;871(1):15-21. Epub 2008 Jun 26. doi: 10.1016/j.jchromb.2008.06.029. PMID: 18635408. PMCID: PMC3782378.
14. Bareford LM, **Phelps MA**, Foraker AB, Swaan PW. *Intracellular processing of riboflavin in human breast cancer cells*. Mol Pharm. 2008 Sept-Oct;5(5):839-48. Epub 2008 Aug 29. doi: 10.1021/mp800046m. PMID: 18754669.
 15. Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, **Phelps MA***. *Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma*. Ther Drug Monit. 2008 Oct;30(5):620-7. doi: 10.1097/FTD.0b013e318185813d. PMID: 18708993. PMCID: PMC3740534.
 16. Morgan RE, Ahn S, Nzimiro S, Fotie J, **Phelps MA**, Cotrill J, Yakovich AJ, Sackett DL, Dalton JT, Werbovets KA. *Inhibitors of tubulin assembly identified through screening a compound library*. Chem Biol Drug Des. 2008 Dec;72(6):513-24. doi: 10.1111/j.1747-0285.2008.00729.x. PMID: 19090918. PMCID: PMC3677961.
 17. Yang X, Zhao X, **Phelps MA**, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ. *A novel liposomal formulation of flavopiridol*. Int J Pharm. 2009 Jan 5;365(1-2):170-4. Epub 2008 Aug 20. doi: 10.1016/j.ijpharm.2008.08.008. PMID: 18778761. PMCID: PMC3035394.
 18. **Phelps MA***, Lin TS*, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT. *Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia*. Blood. 2009 Mar 19;113(12):2637-45. Epub 2008 Nov 3. doi: 10.1182/blood-2008-07-168583. PMID: 18981292. PMCID: PMC2661854.
 19. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, **Phelps MA**, Villalona-Calero MA, Grever MR, Byrd JC. *Phase II study of flavopiridol (alvocidib) in relapsed chronic lymphocytic leukemia (CLL) demonstrating high response rates in genetically high-risk disease*. J Clin Oncol. 2009 Dec 10;27(35):6012-8. Epub 2009 Oct 13. doi: 10.1200/JCO.2009.22.6944. PMID: 19826119. PMCID: PMC2793044.
 20. Lin TS, Stock W, Xu H, **Phelps MA**, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. *A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia (CLL) and acute leukemia*. Leuk Lymphoma. 2009 Dec;50(12):1958-63. doi: 10.3109/10428190903186486. PMID: 19860603.
 21. Blum W*, **Phelps MA***(co-first author), Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR. *Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias*. Haematologica. 2010 Jul;95(7):1098-105. Epub 2010 May 11. doi: 10.3324/haematol.2009.017103. PMID: 20460644. PMCID: PMC2895033.
 22. Ramaswamy B, **Phelps MA**, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH. *A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors*. Invest New Drugs. 2012 Apr;30(2): 629-38. Epub 2010 Oct 12. doi: 10.1007/s10637-010-9563-7. PMID: 20938713. PMCID: PMC3486515.
 23. Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, Dalton JT, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, **Phelps MA**. *Flavopiridol pharmacogenetics: clinical and*

- functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.* PLoS One. 2010 Nov 1;5(11):e13792. doi: 10.1371/journal.pone.0013792. PMID: 21072184. PMCID: PMC2967470.
24. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Nuovo G, Cohn DE, **Phelps M**, Harrington KJ, Pandha HS. *REO-10: a phase 1 study of intravenous reovirus and docetaxel in patients with advanced cancer.* Clin Cancer Res. 2010 Nov 15;16(22):5564-72. Epub 2010 Oct 6. doi: 10.1158/1078-0432.CCR-10-1233. PMID: 20926400. PMCID: PMC3934355.
 25. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, **Phelps MA**, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. *Dose escalation of lenalidomide in relapsed or refractory acute leukemias.* J of Clin Oncol. 2010 Nov 20;28(33):4919-25. Epub 2010 Oct 18. doi: 10.1200/JCO.2010.30.3339. PMID: 20956622. PMCID: PMC3020696.
 26. Kitzmiller JP, Groen DK, **Phelps MA**, Sadee W. *Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.* Cleve Clin J Med. 2011 April;78(4):243-57. doi: 10.3949/ccjm.78a.10145. PMID: 21460130. PMCID: PMC3351041.
 27. Bekaii-Saab T*, **Phelps MA***, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. *A multi-institutional phase II study of selumetinib (AZD6244, ARRY142886) in patients with metastatic biliary cancers.* J Clin Oncol. 2011 Jun 10;29(17):2357-63. Epub 2011 Apr 25. doi: 10.1200/JCO.2010.33.9473. PMID: 21519026. PMCID: PMC3107751.
 28. Hofmeister CC*, Yang X*, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM Jr, Kraut EH, Hicks WJ, Chan KK, Chen C-S, Farag SS, Grever MR, Byrd JC, **Phelps MA**. *Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.* J Clin Oncol. 2011 Sept 1;29(25):3427-34. Epub 2011 Aug 8. doi: 10.1200/JCO.2010.32.4962. PMID: 21825263. PMCID: PMC3164245.
 29. Saradhi UV*, Gupta SV*, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas DM, Grever MR, **Phelps MA****, Chan KK**. *Characterization of silvestrol pharmacokinetics in mice using liquid chromatography–tandem mass spectrometry.* AAPS J. 2011 Sep;13(3):347-56. Epub 2011 Apr 16. doi: 10.1208/s12248-011-9273-x. PMID: 21499689. PMCID: PMC3160157.
 30. Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, **Phelps M**, Johnson AJ, Grever MR, Byrd JC. *Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.* Leukemia. 2011 Sep;25(9):1444-51. Epub 2011 May 24. doi: 10.1038/leu.2011.109. PMID: 21606960. PMCID: PMC3162125.
 31. Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Pan L, Chan KK, Kinghorn AD, **Phelps MA**, Grever MR, Lucas DM. *Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.* AAPS J. 2011 Sep;13(3):357-64. Epub 2011 May 4. doi: 10.1208/s12248-011-9276-7. PMID: 21538216. PMCID: PMC3160166.
 32. Riesen SC, Ni W, Carnes CA, Lindsey KJ, **Phelps MA**, Schober KE. *Pharmacokinetics of oral ivabradine in healthy cats.* J Vet Pharmacol Ther. 2011 Oct;34(5):469-75. Epub 2010 Dec 1. doi: 10.1111/j.1365-2885.2010.01253.x. PMID: 21118419.

33. Park JK*, Kogure T*, Nuovo GJ, Jiang J, He L, Kim JH, **Phelps MA**, Papenfuss TL, Croce CM, Patel T, Schmittgen TD. *miR-221 silencing blocks hepatocellular carcinoma and promotes survival*. *Cancer Res*. 2011 Dec 15;71(24):7608-16. Epub 2011 Oct 18. doi: 10.1158/0008-5472.CAN-11-1144. PMID: 22009537. PMCID: PMC3773601.
34. Yancey-Wrona J, Dallaire B, Bilsky E, Bath B, Burkhart J, Webster L, Magiera D, Yang X, **Phelps M**, Sadee W. *6 β -naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study*. *Pain Med*. 2011 Dec;12(12):1727-37. Epub 2011 Nov 28. doi: 10.1111/j.1526-4637.2011.01279.x. PMID: 22123184.
35. Dulin JA, Drost WT, **Phelps MA**, Santschi EM, Menendez MI, Bertone AL. *Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses*. *Am J of Vet Res*. 2012 Mar;73(3):418-25. doi: 10.2460/ajvr.73.3.418. PMID: 22369536.
36. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, **Phelps MA**, Grever MR, Byrd JC. *Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach*. *Haematologica*. 2012 Mar;97(3):423-7. Epub 2012 Jan 22. doi: 10.3324/haematol.2011.047324. PMID: 22271900. PMCID: PMC3291598.
37. Kitzmiller JP, Embi P, Manickam K, Sweet KM, **Phelps MA**, Jackson RD, Marsh CB, Sadee W. *Institutional Profile. Program in pharmacogenomics at the Ohio State University Medical Center*. *Pharmacogenomics*. 2012 May;13(7):751-6. doi: 10.2217/pgs.12.46. PMID: 22594506. PMCID: PMC3650730.
38. Menendez MI, **Phelps MA**, Hothem EA, Bertone AL. *Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses*. *Am J Vet Res*. 2012 Sep;73(9):1453-61. doi: 10.2460/ajvr.73.9.1453. PMID: 22924728.
39. Bill MA, Nicholas C, Mace TA, Etter JP, Li C, Schwartz EB, Fuchs JR, Young GS, Lin L, Lin J, **Phelps M**, Li P-K, Lesinski GB. *Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines*. *PLoS ONE*. 2012;7(8):e40724. Epub 2012 Aug 10. doi: 10.1371/journal.pone.0040724. PMID: 22899991. PMCID: PMC3416819.
40. He L, Grecula JC, Ling Y, Enzerra MD, Ammirati M, Kendra K, Cavaliere R, Mayr N, McGregor J, Olencki T, Mrozek E, Matharbootham M, Oluigbo C, **Phelps MA**. *Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue*. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2012 Sep 15;905:141-4. Epub 2012 Aug 16. doi: 10.1016/j.jchromb.2012.08.013. PMID: 22925718. PMCID: PMC3856370.
41. Nuovo GJ, Garofalo M, Valeri N, Roulstone V, Volinia S, Cohn DE, **Phelps M**, Harrington KJ, Vile R, Melcher A, Galanis E, Sehl S, Adair R, Scott K, Rose A, Toogood G, Coffey MC. *Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples*. *Mod Pathol*. 2012 Oct;25(10):1333-44. Epub 2012 Jun 15. doi: 10.1038/modpathol.2012.95. PMID: 22699519. PMCID: PMC4275064.
42. George M, **Phelps MA**, Kitzmiller J. *Acetaminophen pediatric dose-selection: caregiver satisfaction regarding the antipyretic efficacy of acetaminophen in children*. *Clin Pediatr (Phila)*. 2012 Nov;51(11): 1030-1. Epub 2012 Aug 13. doi: 10.1177/0009922812456592. PMID: 22890329.
43. Rozewski DM, Herman SE, Towns WH 2nd, Mahoney E, Stefanovski MR, Shin JD, Yang X, Gao Y, Li X, Jarjoura D, Byrd JC, Johnson AJ, **Phelps MA**. *Pharmacokinetics and tissue*

- disposition of lenalidomide in mice*. AAPS J. 2012 Dec;14(4):872-82. Epub 2012 Sep 7. doi: 10.1208/s12248-012-9401-2. PMID: 22956478. PMCID: PMC3475844.
44. Spatola RA, Thangavelu M, Upadhyayula V, Lee S, **Phelps MA**, Chandler HL. *Analysis of the transport of and cytotoxic effects for topical ophthalmic nalbuphine solution in corneal cells*. Am J Vet Res. 2012 Dec;73(12):1987-95. doi: 10.2460/ajvr.73.12.1987. PMID: 23176428.
 45. Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, **Phelps M**, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, Byrd JC, Muthusamy N. *Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies*. Clin Cancer Res. 2013 Jan 15;19(2):347-56. Epub 2012 Dec 3. doi: 10.1158/1078-0432.CCR-12-2046. PMID: 23209030. PMCID: PMC3793126.
 46. Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, **Phelps MA**. *A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol*. Clin Cancer Res. 2013 Mar 1;19(5):1269-80. Epub 2013 Jan 8. doi:10.1158/1078-0432.CCR-12-1092. PMID: 23300276. PMCID: PMC3845832.
 47. Kitzmiller JP, Sullivan DM, **Phelps MA**, Wang D, Sadee W. *CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control*. Drug Metabol Drug Interact. 2013;28(1):59-63. doi: 10.1515/dmdi-2012-0031. PMID: 23314529. PMCID: PMC3681953.
 48. Zhou C, Zhang Y, Yu B, **Phelps MA**, Lee LJ, Lee RJ. *Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes*. Nanomedicine. 2013 May;9(4):504-13. Epub 2012 Oct 29. doi: 10.1016/j.nano.2012.10.002. PMID: 23117046. PMCID: PMC3633702.
 49. Mortazavi A, Ling Y, Martin LK, Wei L, **Phelps MA**, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T. *A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors*. Invest New Drugs. 2013 Jun;31(3):685-95. Epub 2012 Jul 31. doi: 10.1007/s10637-012-9863-1. PMID: 22847785. PMCID: PMC3646991.
 50. Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, **Phelps MA**. *Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease*. Clin Pharmacokinet. 2013 Aug;52(8):705-12. doi: 10.1007/s40262-013-0064-7. PMID: 23588536. PMCID: PMC3720841.
 51. Kasai K, Nakashima H, Liu F, Kerr S, Wang J, **Phelps M**, Potter PM, Goins WB, Fernandez SA, Chiocca EA. *Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs*. Mol Ther Nucleic Acids. 2013 Aug 6;2:e113. doi: 10.1038/mtna.2013.38. PMID: 23922029. PMCID: PMC3759737.
 52. Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, **Phelps MA**, Marcucci G, Blum KA, Blum W. *Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-AAG in combination with bortezomib in relapsed or refractory acute myeloid leukemia*. Leuk Lymphoma. 2013 Sep;54(9):1996-2002. Epub 2013 Jan 24. doi: 10.3109/10428194.2012.760733. PMID: 23256542. PMCID: PMC3860322.
 53. Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, **Phelps MA**, Grever MR, Byrd JC, Flynn JM.

- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.* Leuk Res. 2013 Oct;37(10):1195-9. Epub 2013 Jul 15. doi: 10.1016/j.leukres.2013.06.006. PMID: 23867058. PMCID: PMC3934299.
54. Ding H, Carlton MM, Povoski SP, Milum K, Kumar K, Kothandaraman S, Hinkle GH, Colcher D, Brody R, Davis PD, Pokora A, **Phelps M**, Martin EW Jr, Tweedle MF. *Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.* Bioconjug Chem. 2013 Nov 20;24(11):1945-54. Epub 2013 Oct 31. doi: 10.1021/bc400375f. PMID: 24175669. PMCID: PMC4240220.
55. Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, **Phelps MA**. *Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.* J Pharm Biomed Anal. 2014 Jan;88:262-8. Epub 2013 Sep 2. doi: 10.1016/j.jpba.2013.08.036. PMID: 24095801. PMCID: PMC3860284.
56. Jones JA, Rupert AS, Poi M, **Phelps MA**, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. *Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.* Am J Hematol. 2014 Jan;89(1):19-24. Epub 2013 Sept 30. doi: 10.1002/ajh.23568. PMID: 23959599. PMCID: PMC4150545.
57. Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, **Phelps MA**, Lee LJ, Muthusamy N. *A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.* Nanomedicine. 2014 Feb;10(2):393-400. Epub 2013 Aug 20. doi: 10.1016/j.nano.2013.08.001. PMID: 23969101. PMCID: PMC4134520.
58. Hofmeister CC, Poi M, Bowers MA, Zhao W, **Phelps MA**, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC. *A phase I trial of flavopiridol in relapsed multiple myeloma.* Cancer Chemother Pharmacol. 2014 Feb;73(2):249-57. Epub 2013 Nov 16. doi: 10.1007/s00280-013-2347-y. PMID: 24241210. PMCID: PMC3946636.
59. Grenade C, **Phelps MA**, Villalona-Calero MA. *Race and ethnicity in cancer therapy: what have we learned?* Clin Pharmacol Ther. 2014 Apr;95(4):403-12. Epub 2014 Jan 13. doi: 10.1038/clpt.2014.5. PMID: 24419564.
60. **Phelps MA**, Sparreboom A. *A snapshot of challenges and solutions in cancer drug development and therapy.* Clin Pharmacol Ther. 2014 Apr;95(4):341-6. doi: 10.1038/clpt.2014.15. PMID: 24646480.
61. Kitzmiller JP, **Phelps MA**, Neidecker MV, Apseloff G. *Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly-accredited interdisciplinary training program at the Ohio State University.* Adv Med Educ Pract. 2014 Jun 23;5:191-6. Epub 2014 Jun 23. doi: 10.2147/AMEP.S60986. PMID: 25018660. PMCID: PMC4075108.
62. **Phelps MA***, Stinchcombe TE*, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MA. *Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.* Clin Pharmacol Ther. 2014 Aug;96(2):182-91. Epub 2014 Apr 29. doi: 10.1038/clpt.2014.93. PMID: 24781527. PMCID: PMC4180036.
63. **Phelps MA**, Sparreboom A. *Irinotecan pharmacogenetics: a finished puzzle?* J Clin Oncol. 2014 Aug 1;32(22):2287-9. Epub 2014 Jun 23. doi: 10.1200/JCO.2014.56.3387. PMID: 24958823.

64. Mao Y*, Wang J*, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, **Phelps MA**. *Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry*. J Pharm Biomed Anal. 2014 Sep;98:160-5. Epub 2014 May 23. doi: 10.1016/j.jpba.2014.05.022. PMID: 24927402. PMCID: PMC4180035.
65. Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, **Phelps MA**, Harper E, Johnson AJ, Byrd JC, Andritsos LA. *A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia*. Leuk Res. 2014 Sep;38(9):1025-9. Epub 2014 May 29. doi: 10.1016/j.leukres.2014.05.011. PMID: 25082342. PMCID: PMC4312491.
66. Hosoya K, Couto CG, London CA, Kisseberth WC, **Phelps MA**, Dalton JT. *Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors*. J Am Anim Hosp Assoc. 2014 Nov-Dec;50(6):390-5. Epub 2014 Sep 23. doi: 10.5326/JAAHA-MS-6145. PMID: 25251432.
67. Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, **Phelps MA**, Byrd JC, Johnson AJ. *OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells*. Blood. 2015 Jan 8;125(2):284-95. Epub 2014 Oct 7. doi: 10.1182/blood-2014-06-583518. PMID: 25293770. PMCID: PMC4287637.
68. Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, **Phelps MA**, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. *Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia*. Leukemia. 2015 Feb;29(2):346-55. Epub 2014 Jun 20. doi: 10.1038/leu.2014.199. PMID: 24947019. PMCID: PMC4272672.
69. Wang J, Luzum JA, **Phelps MA**, Kitzmiller JP*. *A liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma*. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Mar 1;983-984:18-25. Epub 2015 Jan 13. doi: 10.1016/j.jchromb.2014.12.029. PMID: 25612772. PMCID: PMC4324004.
70. Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, **Phelps MA**, Byrd JC, Lucas DM, Woyach JA. *Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma*. Leuk Lymphoma. 2015;56(10):2834-40. Epub 2015 Mar 11. doi: 10.3109/10428194.2015.1014368. PMID: 25669927. PMCID: PMC4835239. IF: 3.093
71. Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykan C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, **Phelps MA***, Blum KA*. *Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)*. Am J Hematol. 2015 Apr;90(4):327-33. Epub 2015 Feb 25. doi: 10.1002/ajh.23946. PMID: 25639448. PMCID: PMC4552311. IF: 5.000
72. Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, **Phelps MA**, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N. *ROR1-targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo*. Exp Hematol. 2015 Sep;43(9):770-4.e2. Epub 2015 Apr 29. doi: 10.1016/j.exphem.2015.04.008. PMID: 25937048.

73. Menendez MI, **Phelps MA**, Bertone AL. *Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses*. J Vet Pharmacol Ther. 2016 Feb;39(1):22-6. Epub 2015 Apr 3 doi: 10.1111/jvp.12229. PMID: 25847081.
74. Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, **Phelps MA**, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R. *Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia*. Blood. 2015 Apr 23;125(17):2689-92. Epub 2015 Feb 25. doi: 10.1182/blood-2014-10-607648. PMID: 25716206. PMCID: PMC4408293.
75. Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, **Phelps MA**, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. *The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma*. Br J Haematol. 2015 Jun;169(5):701-10. Epub 2015 Apr 7. doi: 10.1111/bjh.13354. PMID: 25847298. IF: 5.812
76. Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, **Phelps MA**, Villalona-Calero MA, Bekaii-Saab T. *Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer*. Sci Rep. 2015 Jul 10;5:12122. doi: 10.1038/srep12122. PMID: 26161813. PMCID: PMC4894406.
77. Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, **Phelps MA**, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F. *Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers*. J Proteomics. 2016 Mar 16;136:89-98. Epub 2016 Jan 13. doi: 10.1016/j.jprot.2015.12.016. PMID: 26775013. PMCID: PMC4783258.
78. Maddocks K, Hertlein E, Chen TL, Wagner AJ, Ling Y, Flynn J, **Phelps M**, Johnson AJ, Byrd JC, Jones JA. *A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma*. Leuk Lymphoma. 2016 Sep;57(9):2212-5. Epub 2016 Jan 14. doi: 10.3109/10428194.2015.1129536. PMID: 26764527. PMCID: PMC5455147.
79. Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, **Phelps M**, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd. *NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines*. Cancer Immunol Res. 2016 Apr;4(4):323-36. Epub 2016 Feb 10. doi: 10.1158/2326-6066.CIR-15-0168. PMID: 26865456. PMCID: PMC4818694.
80. Rosas LE, Elgamal OA, Mo X, **Phelps MA**, Schmittgen TD, Papenfuss TL. *In vitro immunotoxicity assessment of culture-derived extracellular vesicles in human monocytes*. J Immunotoxicol. 2016 Sep;13(5):652-65. Epub 2016 Apr 14. doi: 10.3109/1547691X.2016.1148089. PMID: 27075513. PMCID: PMC4972675.
81. Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss C, **Phelps MA**, Rossman JS, Pei D. *Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides*. Biochemistry. 2016 May 10;55(18):2601-12. Epub 2016 Apr 28. doi: 10.1021/acs.biochem.6b00226. PMID: 27089101.
82. Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, **Phelps MA**, Chan KK. *Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438)*,

- in Rodents*. AAPS J. 2016 May;18(3):737-45. Epub 2016 Mar 4. doi: 10.1208/s12248-016-9876-3. PMID: 26943915. PMCID: PMC5256597.
83. Oberdick J, Ling Y, **Phelps MA**, Yudovich MS, Schilling K, Sadee W. *Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice*. J Pharmacol Exp Ther. 2016 Jul;358(1):22-30. Epub 2016 May 5. doi: 10.1124/jpet.115.231902. PMID: 27189967. PMCID: PMC4931874.
84. Orienti I, Falconi M, Teti G, Currier MA, Wang J, **Phelps M**, Cripe TP. *Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules*. Pharm Res. 2016 Nov;33(11):2722-35. Epub 2016 Jul 25. doi: 10.1007/s11095-016-1999-9. PMID: 27457066. PMCID: PMC5040747.
85. Kinghorn AD, DE Blanco EJ, Lucas DM, Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ, Wani MC, Stockwell BR, Burdette JE, Swanson SM, Fuchs JR, **Phelps MA**, Xu L, Zhang X, Shen YY. *Discovery of Anticancer Agents of Diverse Natural Origin*. Anticancer Res. 2016 Nov;36(11):5623-5637. doi: 10.21873/anticancer.11146. PMID: 27793884. PMCID: PMC5098703.
86. Sutaria DS, Badawi M, **Phelps MA**, Schmittgen TD. *Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading*. Pharm Res. 2017 May;34(5):1053-1066. Epub 2017 Mar 17. doi: 10.1007/s11095-017-2123-5. PMID: 28315083. PMCID: PMC5565485.
87. Wang J, Zhu X, Kolli S, Wang H, Pearce CJ, Oberlies NH, **Phelps MA**. *Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry*. J Pharm Biomed Anal. 2017 May 30;139:187-192. Epub 2017 Mar 1. doi: 10.1016/j.jpba.2017.02.051. PMID: 28284083. PMCID: PMC5399420.
88. **Phelps MA**. *Rituximab immunotherapy: it's getting personal*. Blood. 2017 May 11;129(19):2595-2596. doi: 10.1182/blood-2017-03-772061. PMID: 28495922.
89. Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, **Phelps MA**, Bartlett NL, Blum KA. *A Phase I/II Trial of Panobinostat in Combination with Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma*. Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):347-353. Epub 2017 May 22. doi: 10.1016/j.clml.2017.05.008. PMID: 28622959. PMCID: PMC6033275.
90. Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A, Jiang J, Elgamal OA, Mo X, Perle K, Chalmers J, Schmittgen TD, **Phelps MA**. *Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells*. J Extracell Vesicles. 2017 Jun 6;6(1):1324730. Epub 2017 Jun 6. doi: 10.1080/20013078.2017.1324730. PMID: 28717420. PMCID: PMC5505007.
91. Sutaria DS, Jiang J, Elgamal OA, Pomeroy SM, Badawi M, Zhu X, Pavlovicz R, Azevedo-Pouly ACP, Chalmers J, Li C, **Phelps MA**, Schmittgen TD. *Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery*. J Extracell Vesicles. 2017 Jun 14;6(1):1333882. Epub 2017 Jun 14. doi: 10.1080/20013078.2017.1333882. PMID: 28717424. PMCID: PMC5505005.
92. Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, **Phelps MA**, Hofmeister CC. *Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant*. Mol Carcinog. 2017 Jul;56(7):1722-1732. Epub 2017 Feb 16. doi: 10.1002/mc.22626. PMID: 28150872.
93. Bins S, van Doorn L, **Phelps MA**, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD. *Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide*. Clin Transl Sci. 2017 Jul;

- 10(4)271-279. Epub 2017 Mar 31. doi: 10.1111/cts.12458. PMID: 28371445. PMCID: PMC5504481.
94. Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, **Phelps MA**, Houghton P, London CA. *Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma*. PLoS One. 2017;12(7):e0181885. Epub 2017 Jul 27. doi: 10.1371/journal.pone.0181885. PMID: 28750090. PMCID: PMC5531494.
95. Mani R, Yan R, Mo X, Chen CS, **Phelps MA**, Klisovic R, Byrd JC, Kisseberth WC, London CA, Muthusamy N. *Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma*. Vet Comp Oncol. 2017 Sep;15(3):1115-1118. Epub 2016 May 2. doi: 10.1111/vco.12221. PMID: 27136276. PMCID: PMC5093090.
96. Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, **Phelps MA**. *Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial*. Clin Pharmacol Ther. 2017 Sep;102(3):511-519. Epub 2017 May 26. doi: 10.1002/cpt.644. PMID: 28160288. PMCID: PMC5821248.
97. Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, **Phelps M**, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Sauntharajah Y. *Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study*. PLoS Med. 2017 Sep 7;14(9):e1002382. Epub 2017 Sep 7. doi: 10.1371/journal.pmed.1002382. PMID: 28880867. PMCID: PMC5589090.
98. Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, **Phelps MA**, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC. *A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas*. Leuk Lymphoma. 2017 Oct;58(10):2310-2318. Epub 2017 Mar 7. doi: 10.1080/10428194.2017.1298751. PMID: 28270022. PMCID: PMC5489371.
99. Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, **Phelps MA**, Carson WE. *Nitric oxide mediated inhibition of antigen presentation from DCs to CD4(+) T cells in cancer and measurement of STAT1 nitration*. Sci Rep. 2017 Nov 13;7(1):15424. doi: 10.1038/s41598-017-14970-0. PMID: 29133913. PMCID: PMC5684213. Erratum in: Sci Rep. 2018 Mar 6;8(1):4203. doi: 10.1038/s41598-018-21306-z. PMID: 29133913. PMCID: PMC5840347.
100. Sborov DW*, Cho YK*, Cottini F*, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, **Phelps MA****, Hofmeister CC**. *G-CSF improves safety when you start the day after autologous transplant in multiple myeloma*. Leuk Lymphoma. 2017 Dec;58(12):2947-2951. Epub 2017 May 16. doi: 10.1080/10428194.2017.1318436. PMID: 28509594. PMCID: PMC6607907.
101. Banasavadi-Siddegowda YK, Welker AM, An M, Yang X, Zhou W, Shi G, Imitola J, Li C, Hsu S, Wang J, **Phelps M**, Zhang J, Beattie CE, Baiocchi R, Kaur B. *PRMT5 as a druggable target for glioblastoma therapy*. Neuro Oncol. 2018 May;20(6):753-763. doi:10.1093/neuonc/nox206. PMID: 29106602. PMCID: PMC5961180.
102. Badawi M, Kim J, Dauki A, Sutaria D, Motiwala T, Reyes R, Wani N, Kolli S, Jiang J, Coss CC, Jacob ST, **Phelps MA**, Schmittgen TD. *CD44 positive and sorafenib insensitive*

- hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128*. *Oncotarget*. 2018 May 25;9(40):26032-26045. Epub 2018 May 25. doi: 10.18632/oncotarget.25430. PMID: 29899840. PMCID: PMC5995255.
103. Young AN, Herrera D, Huntsman AC, Korkmaz MA, Lantvit DD, Mazumder S, Kolli S, Coss CC, King S, Wang H, Swanson SM, Kinghorn AD, Zhang X, **Phelps MA**, Aldrich LN, Fuchs JR, Burdette JE. *Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition*. *Mol Cancer Ther*. 2018 Oct;17(10):2123-2135. Epub 2018 Jul 17. doi: 10.1158/1535-7163.MCT-17-1195. PMID: 30018048. PMCID: PMC6168422.
104. Cho YK, Irby DJ, Li J, Sborov DW, Mould DR, Badawi M, Dauki A, Lamprecht M, Rosko AE, Fernandez S, Hade EM, Hofmeister CC, Poi M, **Phelps MA**. *Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients with Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant*. *CPT Pharmacometrics Syst Pharmacol*. 2018 Nov;7(11):748-758. Epub 2018 Oct 20. doi: 10.1002/psp4.12345. PMID: 30343510. PMCID: PMC6263666.
105. Haraldsdottir S, Janku F, Poi M, Timmers C, Geyer S, Schaaf LJ, Sexton J, Wei L, Thurmond J, Velez-Bravo V, Stepanek VM, Bertino EM, Kendra K, Mortazavi A, Subbiah V, **Phelps M**, Shah MH. *Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies*. *JCO Precision Oncology*. Epub 2018 May 14.
106. Coss CC, Clinton SK, **Phelps MA**. *Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?* *Clin Cancer Res*. 2018 Dec 1;24(23):5787-5789. Epub 2018 Jul 17. doi: 10.1158/1078-0432.CCR-18-1847. PMID: 30018117. PMCID: PMC6279566.
107. Poi MJ, Li J, Johnson JA, Cho YK, Sborov DW, **Phelps MA**, Hofmeister CC. *A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients*. *Anticancer Res*. 2019 Jan;39(10):67-72. doi: 10.21873/anticancer.13080. PMID: 30591441.
108. Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce CJ, Xie Z, Kulp SK, Coss CC, **Phelps MA**, Albers T, Lebedyeva IO, Liu K. *SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion*. *Cancer Immunol Res*. 2019 March;7(3):414-427. Epub 2019 Jan 4. doi: 10.1158/2326-6066.CIR-18-0126. PMID: 30610059. PMC: PMC6397681.
109. DasAbdel-Mageed AB, Adamidi C, Adelson PD, Akat KM, Alsop E, Ansel KM, Arango J, Aronin N, Avsaroglu SK, Azizian A, Balaj L, Ben-Dov IZ, Bertram K, Bitzer M, Billeloch R, Bogardus KA, Breakefield XO, Calin GA, Carter BS, Charest A, Chen CC, Chitnis T, Coffey RJ, Courtright-Lim A, Das S, Datta A, DeHoff P, Diacovo TG, Erle DJ, Etheridge A, Ferrer M, Franklin JL, Freedman JE, Galas DJ, Galeev T, Gandhi R, Garcia A, Gerstein MB, Ghai V, Ghiran IC, Giraldez MD, Goga A, Gogakos T, Goilav B, Gould SJ, Guo P, Gupta M, Hochberg F, Huang B, Huentelman M, Hunter C, Hutchins E, Jackson AR, Kalani MYS, Kanlikilicer P, Karaszti RA, Van Keuren-Jensen K, Khvorova A, Kim Y, Kim H, Kim TK, Kitchen R, Kraig RP, Krichevsky AM, Kwong RY, Laurent LC, Lee M, L'Etoile N, Levy SE, Li F, Li J, Li X, Lopez-Berestein G, Lucero R, Mateescu B, Martin AC, Max KEA, McManus MT, Mempel TR, Meyer C, Milosavljevic A, Mondal D, Mukamal KJ, Murillo OD, Muthukumar T, Nickerson DA, O'Donnell CJ, Patel DJ, Patel T, Patton JG, Paul A, Peskind ER, **Phelps MA**, Putterman C, Quesenberry PJ, Quinn JF, Raffai RL, Ranabothu S, Rao SJ, Rodriguez-Aguayo C, Rosenzweig A, Roth ME, Rozowsky J, Sabatine MS, Sakhanenko NA, Saugstad JA, Schmittgen TD, Shah N, Shah R, Shedden K, Shi J, Sood AK, Sopeyin A, Spengler RM, Spetzler R, Srinivasan S, Subramanian SL, Suthanthiran M, Tanriverdi K, Teng Y, Tewari M, Thistlethwaite W, Tuschl T, Urbanowicz KK, Vickers KC, Voinnet O, Wang K, Weaver AM,

- Wei Z, Weiner HL, Weiss ZR, Williams Z, Wong DTW, Woodruff PG, Xiao X, Yan IK, Yeri A, Zhang B, Zhang HG. *The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research*. Cell. 2019 Apr 4;177(2): 231-242. doi: 10.1016/j.cell.2019.03.023. PMID: PMC6601620. PMCID: PMC6601620.
110. Badawi M, Coss CC, **Phelps MA**. Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al. Eur J Cancer. 2019 Jun;114:25-26. Epub 2019 Apr 19. doi: 10.1016/j.ejca.2019.02.017. PMID: 31009820.
111. Hughes JH, **Phelps MA**, Upton RN, Reuter SE, Gao Y, Byrd JC, Grever MR, Hofmeister CC, Marcucci G, Blum W, Blum KA, Foster DJR. *Population pharmacokinetics of lenalidomide in patients with B-cell malignancies*. Br J Clin Pharmacol. 2019 May;85(5):924-934. Epub 2019 Feb 27. doi: 10.1111/bcp.13873; PMID: 30672004; PMCID: PMC6475687.
112. Yoo JY, Swanner J, Otani Y, Nair M, Park F, Banasavadi-Siddegowda Y, Liu J, Jaime-Ramirez AC, Hong B, Geng F, Guo D, Bystry D, **Phelps M**, Quadri H, Lee TJ, Kaur B. *oHSV therapy increases trametinib access to brain tumors and sensitizes them in vivo*. Neuro Onco. 2019 Sept;21(19):1131-1140. Epub 2019 May 7. doi: 10.1093/neuonc/noz079. PMID: 31063549. PMCID: PMC7571492
113. Jeon JY, Zhao Q, Buelow DR, **Phelps M**, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B. *Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML*. Invest New Drugs. 2020 Apr;38(2):340-349. Epub 2019 May 17. doi: 10.1007/s10637-019-00786-4. PMID: 31102119.
114. Chiang CL, Goswami S, Frizzera FW, Xie Z, Yan PS, Bundschuh R, Walker LA, Huang X, Mani R, Mo XM, Baskar S, Rader C, **Phelps MA**, Marcucci G, Byrd JC, Lee LJ, Muthusamy N. *ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in CLL mouse model*. Blood. 2019 Aug 1;134(5):432-444. Epub 2019 May 31. doi: 10.1182/blood.2018882290. PMID: 31151986; PMCID: PMC6676131. IF: 16.562
115. Hughes JH, Upton RN, Reuter SE, **Phelps MA**, Foster DJR. *Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis*. J Pharm Pharmacol. 2019 Nov;71(11):1635-1644. Epub 2019 Aug 14. doi:10.1111/jphp.13154. PMID: 31412422.
116. Hughes JH, Upton RN, Reuter SE, Rozewski DM, **Phelps MA**, Foster DJR. *Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice*. Cancer Chemother Pharmacol. 2019 Nov;84(5):1073-1087. Epub 2019 Sep 6. doi: 10.1007/s00280-019-03941-z. PMID: 31493176 PMCID: PMC7375688 DOI: 10.1007/s00280-019-03941-z
117. Persaud AK, Li J, Johnson JA, Seligson N, Sborov DW, Duah E, Cho YK, Wang D, **Phelps MA**, Hofmeister CC, Poi MJ. *XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant*. Mol Carcinog. 2019 Dec;58(12):2327-2339. Epub 2019 Sep 22. doi: 10.1002/mc.23121. PMID: 31544312.
118. Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhatnagar B, Walsh K, Geyer S, Zhao Q, Garzon R, Marcucci G, **Phelps MA**, Walker AR. *Phase I study of AR-42 and decitabine in acute myeloid leukemia*. Leuk Lymphoma. 2020 Feb 8:1-9. doi: 10.1080/10428194.2020.1719095. [Epub ahead of print] PMID: 32037935.
119. Sardesai S, Badawi M, Mrozek E, Morgan E, **Phelps M**, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M,

- Grever M, Carson W, Ramaswamy B, Wesolowski R. *A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer*. Invest New Drugs. 2020 Oct;38(5):1400-1410. doi: 10.1007/s10637-020-00895-5. Epub 2020 Jan 17. PubMed PMID: 31953695.
120. Liva SG, Tseng YC, Dauki AM, Sovic MG, Vu T, Henderson SE, Kuo YC, Benedict JA, Zhang X, Remaily BC, Kulp SK, Campbell M, Bekaii-Saab T, **Phelps MA**, Chen CS, Coss CC. *Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor*. EMBO Mol Med. 2020 Feb 7;12(2):e9910. doi: 10.15252/emmm.201809910. Epub 2020 Jan 13. PMID: 31930715. PMCID: PMC7005646.
121. Li J, Seligson N, Zhang X, Johnson J, Vangundy Z, Wang D, **Phelps M**, Hofmeister C, Sadee W, Poi MJ. Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Anticancer Res. 2020 Oct;40(10):5707-5713. doi: 10.21873/anticancer.14585. PubMed PMID: 32988896.
122. Jain R, Coss C, Whooley P, **Phelps M**, Owen DH. *The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer*. Curr Oncol Rep. 2020 May 15;22(6):54. doi: 10.1007/s11912-020-00916-9. PMID: 32409907.
123. Xie Z*, Chen M*, Goswami S, Mani R, Wang D, Kulp SK, **Coss CC**, Schaaf LJ, Cui F, Byrd JC, Jennings RN, Schober KK, Freed C, Lewis S, Malbrue R, Muthusamy N, Bennett C, Kisseberth WC**, **Phelps MA****. *Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats*. AAPS J. 2020 Jul 16;22(4):92. PMID: 32676788; PMCID: PMC7814188.
124. Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, **Phelps MA**, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS. *A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome*. Am J Hematol. 2020 Aug 10. PMID: 32777116. PMCID: PMC7821016 DOI: 10.1002/ajh.25958
125. Wang H, Radomska HS, Phelps MA. Replication Study: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Elife. 2020 Oct 19;9. doi: 10.7554/eLife.56651. PubMed PMID: 33073769; PubMed Central PMCID: PMC7572125.
126. Thangavadivel S, Zhao Q, Epperla N, Rike L, Mo X, Badawi M, Bystry DM, **Phelps MA**, Andritsos LA, Rogers KA, Jones J, Woyach JA, Byrd JC, Awan FT. Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 Dec 1;26(23):6187-6195. doi: 10.1158/1078-0432.CCR-20-1280. Epub 2020 Sep 21. PubMed PMID: 32958702.
127. Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, Poi M, **Phelps MA**, Liva SG, Coss CC, Wang J, Khountham S, Monk P, Shapiro CL, Piekarz R, Hofmeister CC, Welling DB, Mortazavi A. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemother Pharmacol. 2021 Jan 25;. doi: 10.1007/s00280-020-04229-3. PubMed PMID: 33492438.
128. Helms TH, Mullins RD, Thomas-Ahner JM, Kulp SK, Campbell MJ, Lucas F, Schmidt N, LeMoine DM, Getaneh S, Xie Z, Phelps MA, Clinton SK, Coss CC. *Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks*. Sci Rep. 2021 Feb 11;11(1):3646. doi: 10.1038/s41598-021-82252-x. PMID: 33574348 Free PMC article.
129. Castillo AMM*, Vu TT*, Liva SG, Chen M, Xie Z, Thomas J, Remaily B, Guo Y, Subrayan

UL, Costa T, Helms TH, Irby DJ, Kim K, Owen DH, Kulp SK, Mace TA, Phelps MA**, Coss CC**. Single-dose pembrolizumab in murine cancer-cachexia models replicates elevated catabolic pembrolizumab clearance in humans. *JCSM Rapid Communications*. In Press. 2021. <https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.32>

Abstracts and Presentations

1. EY Zhang, **MA Phelps**, PW Swaan. *Membrane topology and critical residues for substrate interaction with the apical sodium-dependent bile acid transporter, ASBT*. American Association of Pharmaceutical Scientists Annual Meeting, Denver, CO, October 2001.
2. **MA Phelps**, SN Huang, PW Swaan. *Riboflavin is Transported Through a Receptor-Mediated Endocytosis Pathway in BeWo Cell Monolayers*. American Association of Pharmaceutical Scientists Drug Transport Meeting, Atlanta, GA, February 2003.
3. **MA Phelps**, AB Foraker, W Gao, JT Dalton, PW Swaan. *Intramolecular Resonance Energy Transfer in a Rhodamine-Riboflavin Conjugate: A Novel Tool for One- and Two-Photon Imaging of Riboflavin Transport and Trafficking*. Biophysical Society Annual Meeting, Baltimore, MD, February 2004.
4. W Gao, PJ Reiser, JD Kearbey, **MA Phelps**, CC Coss, DD Miller, JT Dalton. *Effects of a Novel Selective Androgen Receptor Modulator (SARM) on Skeletal Muscle Mass and Strength in Castrated Male Rats*. The Endocrine Society Annual Meeting, New Orleans, LA, June 2004.
5. **MA Phelps**, AB Foraker, W Gao, JT Dalton, PW Swaan. *Physicochemical and Spectral Characterization of a Novel Rhodamine-Riboflavin Conjugate*. American Association of Pharmaceutical Scientists Annual Meeting, Baltimore, MD, November 2004.
6. **MA Phelps**, W Gao, J Chen, N Hussainzada, PW Swaan, JT Dalton. *Differential Absorption of Riboflavin in Breast Cancer Cell Models*. American Association of Pharmaceutical Scientists Drug Transport Meeting, Parsippany, NJ, March 2005.
7. **MA Phelps**, PW Swaan, JT Dalton. *Riboflavin Carrier Protein and Riboflavin in Breast Tumor Targeting*. Department of Defense Breast Cancer Research Program, Era of Hope Annual Meeting, Philadelphia, PA, June 2005.
8. Eunju Hurh, **Mitch A. Phelps**, Di Wu, John C. Byrd, Michael R. Grever, James T. Dalton. *Population Pharmacokinetic Modeling of Flavopiridol in Chronic Lymphocytic Leukemia Patients*, American Association of Pharmaceutical Scientists, 2006.
9. **MA Phelps**, E Hurh, B Wulff, T Oberyszyn, J Dalton. *Development of a sensitive analytical method for simultaneous quantification of rapamycin and cyclosporine in mouse whole blood and determination of their pharmacokinetic interactions with intraperitoneal delivery*. American Association of Pharmaceutical Scientists, 2006.
10. JC Byrd, TS Lin, JT Dalton, **MA Phelps**, D Wu, B Fischer, M Moran, M Brooker, K Blum, B Rovin, S Broering, L Schaaf, AJ Johnson, DM Lucas, N Heerema, G Lozanski, J Ramon-Suarez, AD Colevas, MR Grever. *Pharmacologically Derived Schedule of Flavopiridol Has Significant Efficacy in Refractory, Genetically High Risk Chronic Lymphocytic Leukemia (CLL)*. American Society for Clinical Oncology Annual Meeting, Atlanta, GA, June 2006.
11. **MA Phelps**, D Wu, JC Byrd, TS Lin, K Blum, L Schaaf, AJ Johnson, AD Colevas, MR Grever, JT Dalton. *Pharmacokinetic and Pharmacodynamic Correlations of Flavopiridol in the Treatment of Chronic Lymphocytic Leukemia*. American Society for Clinical Oncology Annual Meeting, Atlanta, GA, June 2006.
12. Bhuvana Ramaswamy, Ju-Ping Lai, **Mitch A. Phelps**, James T. Dalton, Daria Arbogast, Deidre Wilkins, Dimitrios Colevas, John Byrd, Michael Grever, Manisha Shah. *A phase I study of flavopiridol using an alternative schedule of 30-min loading dose followed by a 4-*

- hour IV infusion in patients (pts) with advanced solid tumors. American Association for Cancer Research, 2007.
13. Brian C. Wulff, Kathy L. Tober, **Mitch A. Phelps**, F.J. Duncan, Anne M. Vanbuskirk, Donna F. Kusewitt, Tatiana M. Oberyszyn. *Effects of Cyclosporine A and Sirolimus on progression of UVB induced skin tumors*. American Association for Cancer Research, 2007.
 14. **MA Phelps**, D Wu, Z Dai, E Hurh, AJ Johnson, KL Farley, LJ Schaaf, W Sadee, TS Lin, JC Byrd, MR Grever, JT Dalton. *Population Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Flavopiridol with a Clinically Active Dosing Schedule in Patients with Chronic Lymphocytic Leukemia*. American Association of Pharmaceutical Scientists Drug Transport Focus Group, 2007.
 15. Ju-Ping Lai, **Mitch A. Phelps**, Manisha Shah, Bhuvaneshwari Ramaswamy, John C. Byrd, Michael R. Grever, James T. Dalton. *Population Pharmacokinetic Modeling of Flavopiridol in Patients with Advanced Solid Tumors*. American Association of Pharmaceutical Scientists, 2007.
 16. TS Lin, LA Andritsos, JA Jones, B Fischer, NA Heerema, KA Blum, JM Flynn, ME Moran, SM Mitchell, G Lozanski, LJ Schaaf, AJ Johnson, LL Smith, AJ Wagner, CA Raymond, **MA Phelps**, JT Dalton, MR Grever, JC Byrd. *The Cyclin Dependent Kinase (CDK) Inhibitor Flavopiridol Is Highly Active in Relapsed, Genetically High-Risk Chronic Lymphocytic Leukemia (CLL)*. American Society of Clinical Oncology, 2008.
 17. Xiaojuan Yang, Xiaobin Zhao, **Mitch A. Phelps**, Qing Liu, Dolly Rozewski, James T. Dalton, Robert J. Lee. *Preparation and Characterization of Flavopiridol Liposome and Its Pharmacokinetics in Mice*. American Association of Pharmaceutical Scientists, 2008.
 18. Wenjun Ni, Katie A. Albanese, Katherine L. Farley, Amy J. Johnson, David M. Lucas, Zunyan Dai, John C. Byrd, Michael R. Grever, James T. Dalton, Wolfgang Sadee, **Mitch A. Phelps**. *Clinical Pharmacokinetics and Pharmacogenetics of Flavopiridol*. American Association of Pharmaceutical Scientists Annual Meeting, 2009.
 19. **Mitch A. Phelps**, Danxin Wang, Josephine E. Aimiwu, Sherri L. Starrett, Audrey C. Papp, Ahmed A. Ghany, William J. Hicks, Kavitha V. Kosuri, Gregory A. Otterson, Mark A. Socinski, Thomas E. Stinchcombe, Weiqiang Zhao, Larry J. Schaaf, Sanford H. Barsky, Kenneth K. Chan, Wolfgang Sadee, Miguel A. Villalona-Calero. *Erlotinib in African Americans with lung cancer: a prospective, clinical, molecular, pharmacokinetic and pharmacogenetic characterization*. American Association for Cancer Research, Denver, CO, 2009.
 20. Jason C. Chandler, Rebecca B. Klisovic, **Mitch A. Phelps**, Alison Walker, Ramiro Garzon, Xiaoxia Yang, Larry Schaaf, Sebastian Schwind, Heiko Becker, Shujun Liu, Chris Hickey, Cheryl Kefauver, Jon Mickle, Steven M. Devine, Michael R. Grever, John C. Byrd, Guido Marcucci, William Blum. *Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia*. American Society of Hematology, 2009.
 21. Tanios Bekaii-Saab, **Mitch Phelps**, Xiaobai Li, Motoyasu Saji, Kavitha Kosuri, Laura Goff, John Kauh, Bert O'Neil, Christopher South, James Thomas, Stephanie Balsom, Nicole Chattah, Catherine Balint, Ryan Liersemann, Vasily Vasko, William Marsh, L. Austin Doyle, Matthew Ringel, Miguel Villalona Calero. *A Multi-institutional Study of AZD6244 in Patients with Advanced Biliary Cancers*. American Association for Cancer Research, Denver, CO, 2009.
 22. Craig C. Hofmeister, Ping Chen, Zhongfa Liu, Darlene M. Rozewski, Xiao X. Yang, **Mitch A. Phelps**, Don M. Benson, Yvonne Efebera, Kenneth K. Chan, Sherif S. Farag, Michael R.

- Grever. *Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma*. American Society of Hematology, 2009.
23. JC Grecula, A Ammirati, **M Phelps**, K Kendra, R Cavaliere, B McCracken, J Radawski, L Wei, E Mrozek, N Mayr. *Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients with 1- 3 Brain Metastases from Solid Malignancies*. American Society of Clinical Oncology Annual Meeting, 2010.
 24. Lei He, Yonghua Ling, Xiaoxia Yang, Zhongfa Liu, Stacey L. Fossey, Cheryl A. London, Chenglong Li, Pui-Kai Li, James R. Fuchs, Gregory B. Lesinski, **Mitch A. Phelps**. *Pre-Clinical Pharmacokinetics of FLLL32, a Curcumin-derived Selective JAK2/STAT3 Inhibitor*. American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, 2010.
 25. Wenjun Ni, Jia Ji, Amy J. Johnson, Audrey Papp, Wolfgang Sadee, John C. Byrd, Michael R. Grever, **Mitch A. Phelps**. *Influence of Glutathione-S-Transferase Pharmacogenetics in a Population Pharmacokinetic-Pharmacodynamic Model of Flavopiridol*. American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, 2010.
 26. Jia Ji, Wenjun Ni, Amy J. Johnson, John C. Byrd, Michael R. Grever, **Mitch A. Phelps**. *Population pharmacokinetic-pharmacodynamic model for flavopiridol and its primary glucuronide metabolite*. American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, 2010.
 27. **Mitch A. Phelps**, David E. Cohn, David M. O'Malley, Lai Wei, Deidre Wilkins, Angela Campbell, Larry J. Schaaf, Matthew C. Coffey, James A. Zwiebel, Miguel A. Villalona-Calero, Michael R. Grever, Gerard J. Nuovo. *Reovirus Replication in Ovarian and Peritoneal Tumors after Intravenous Administration*. American Association for Cancer Research, Washington, DC, 2010.
 28. Jeffrey A. Jones, Leslie Andritsos, Robert Baiocchi, Don Benson, Kristie A. Blum, Beth Christian, Deidre Deam, Joseph Flynn, Amy J. Johnson, **Mitch A. Phelps**, Pierluigi Porcu, John C. Byrd, Michael R. Grever. *Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma*. American Society of Hematology, 2010.
 29. Kristie A. Blum, Amy S. Ruppert, Jennifer A. Woyach, Jeffrey Jones, Leslie Andritsos, Joseph Flynn, Brad Rovin, **Mitch A. Phelps**, Amy J. Johnson, Michael R. Grever, and John C. Byrd. *Risk Factors for Tumor Lysis Syndrome (TLS) in patients with Chronic Lymphocytic Leukemia (CLL) treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol*. American Society of Hematology, 2010.
 30. Amir Mortazavi, Deidra Deam, Yonghua Ling, Erica J. Harper, **Mitch A. Phelps**, Igor J. Espinoza-Delgado, J. Paul Monk, Gregory A. Otterson, Michael R. Grever, Tanios Bekaii-Saab. *A Phase I Study of Prolonged Infusion of Triapine in Combination with a Fixed Dose Rate of Gemcitabine in Patients with Advanced Solid Tumors*. American Society of Clinical Oncology Annual Meeting, 2010.
 31. Jinmai Jiang, Jong-Kook Park, Ji Hye Kim, Lei He, Gerard J. Nuovo, Tushar Patel, **Mitch A. Phelps**, Thomas D. Schmittgen. *Pharmacokinetic and pharmacodynamic evaluation of cholesterol labeled and unlabeled miR-221 antagomiRs in mice*. American Association for Cancer Research Annual Meeting, Washington, DC, 2010.
 32. Xiaoxia Yang, Craig C. Hofmeister, Darlene M. Rozewski, Seungsoo Lee, Ping Chen, Amy J. Johnson, Zhongfa Liu, Erinn M. Hade, Jia Ji, Larry J. Schaaf, Don M. Benson Jr., Eric H. Kraut, William J. Hicks, Kenneth K. Chan, Ching-Shih Chen, Sherif S. Farag, Michael R. Grever, John C. Byrd, **Mitch A. Phelps**. *P-glycoprotein-mediated interaction of lenalidomide and temsirolimus in a phase 1 study in patients with multiple myeloma*. Great Lakes Drug Metabolism Discussion Group Meeting, 2010.

33. Jeffrey A. Jones, Leslie Andritsos, Robert Baiocchi, Don Benson, Kristie A. Blum, Beth Christian, Deidre Deam, Joseph Flynn, Amy J. Johnson, **Mitch A. Phelps**, Pierluigi Porcu, John C. Byrd, Michael R. Grever. *Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma*. American Society of Hematology Annual Meeting, 2010.
34. Deborah M. Stephens, Amy S. Ruppert, Kristie Blum, Jeffrey Jones, Joseph M. Flynn, Amy J. Johnson, Jia Ji, **Mitchell Phelps**, Michael R. Grever, John C. Byrd. *Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia is Feasible and Not Associated with Adverse Outcome when Compared to Younger Patients*. American Society of Hematology Annual Meeting, 2010.
35. Kristie A. Blum, Amy S. Ruppert, Jennifer A. Woyach, Jeffrey Jones, Leslie Andritsos, Joseph Flynn, Brad Rovin, **Mitchell Phelps**, Amy J. Johnson, Michael R. Grever, John C. Byrd. *Risk Factors for Tumor Lysis Syndrome (TLS) in patients with Chronic Lymphocytic Leukemia (CLL) treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol*. American Society of Hematology Annual Meeting, 2010.
36. Xiaoxia Yang, Craig C. Hofmeister, Darlene M. Rozewski, Seungsoo Lee, Ping Chen, Amy J. Johnson, Zhongfa Liu, Erinn M. Hade, Jia Ji, Larry J. Schaaf, Don M. Benson Jr., Eric H. Kraut, William J Hicks, Kenneth K. Chan, Ching-Shih Chen, Sherif S. Farag, Michael R. Grever, John C. Byrd, **Mitch A. Phelps**. *The Contribution of P-glycoprotein to Clinical Pharmacokinetic Interactions between Lenalidomide and Temsirolimus*. American Association for Cancer Research Annual Meeting, 2011.
37. Darlene M. Rozewski, William H. Towns II, Matthew R. Stefanovski, Xiaoxia Yang, John C. Byrd, *Amy J. Johnson, ***Mitch Phelps**. *A pharmacokinetic characterization of oral, intravenous and intraperitoneal administrations of lenalidomide in mice*. The Ohio State University College of Pharmacy Research Day, 2011.
38. James R. Mansfield, Gerard Nuovo, Matt Coffey, **Mitch Phelps**, David Cohn. *Cellular context in epigenetics: per-cell quantitation of miR-let-7d and its putative target in caspase-3 in reovirus infected cancer cells*. American Association for Cancer Research Annual Meeting, 2011.
39. Sneha V. Gupta, Ellen J. Sass, Melanie E. Davis, Ryan B. Edwards, Gerard Lozanski, Nyla A. Heerema, Amy Lehman, Xiaoli Zhang, David Jarjoura, John C. Byrd, Kenneth K. Chan, A. Douglas Kinghorn, Michael Grever, **Mitch A. Phelps**, David M. Lucas. *Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with rapamycin*. American Association for Cancer Research Annual Meeting, 2011.
40. Jong Kook Park, Takayuki Kogure, Gerard J. Nuovo, Lei He, Ji Hye Kim, **Mitch A. Phelps**, Carlo M. Croce, Tushar Patel, Thomas D. Schmittgen. *Silencing of miR-221 with anti-microRNA oligonucleotides is an effective therapeutic for hepatocellular carcinoma*. American Association for Cancer Research Annual Meeting, 2011.
41. Matthew A. Bill, Courtney Nicholas, Thomas Mace, Lei He, Yonghua Ling, **Mitch Phelps**, Chenglong Li, Eric B. Schwartz, James R. Fuchs, Gregory S. Young, Li Lin, Jiayuh Lin, Pui Kai Li, Gregory B. Lesinski. *A novel bioavailable small molecule curcumin analog FLLL100-P inhibits STAT3 signaling and induces apoptosis in melanoma cells*. Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2011.
42. Yonghua Ling, Donald O. Mutti, **Mitch A. Phelps**. *Deuterated 25OHD3 as a substitute for 25OHD3 quantification in human plasma/serum: a novel strategy for endogenous species quantification*. American Association of Pharmaceutical Scientists Annual Meeting, 2011.
43. Kristie A. Blum, Lai Wei, Jeffrey A. Jones, Leslie Andritsos, Joseph Flynn, Nyla Heerema,

- Mitchell Phelps**, Amy J. Johnson, Michael R. Grever, and John C. Byrd. *Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial*. American Society of Hematology Annual Meeting, 2011.
44. Beth Christian, Lapo Alinari, Jeffrey A. Jones, Don M. Benson Jr., Joseph M. Flynn, Pierluigi Porcu, Mark Lustberg, **Mitchell Phelps**, Ming Poi, Diana Chung, Carl Quinion, John C. Byrd, William A. Wegener, David M. Goldenberg, Robert A. Baiocchi, Kristie A. Blum. *A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma*. American Society of Hematology Annual Meeting, 2011.
 45. Deborah M. Stephens, Joseph M. Flynn, Kami Maddocks, Kristie A. Blum, Leslie Andritsos, Robert Baiocchi, Jeffrey Jones, **Mitch Phelps**, Amy J. Johnson, Lisa Smith, Michael R. Grever, John C. Byrd. *Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients with High-Risk B-cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)*. American Society of Hematology Annual Meeting, 2012.
 46. Lei He, John Grecula, Yonghua Ling, Xiaoxia Yang, Michael Enzerra, Jeffrey Cotrill, Mario Ammirati, Kari Kendra, Robert Cavaliere Ewa Mrozek, Barbara McCracken-Bussa, Laura Mayer, Nina Mayr, Lai Wei, **Mitch Phelps**. *Pharmacokinetics of Bendamustine in Patients with Brain Metastases from Solid Tumors: Evaluation of Bendamustine Blood-Brain Barrier (BBB) Penetration*. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Washington, DC, March 2012.
 47. Darlene M. Rozewski, Xiaoxia Yang, Yonghua Ling, Amy J. Johnson, John C. Byrd, Kristie A. Blum, **Mitchell Phelps**. *Pharmacokinetics of Concomitant Lenalidomide and Flavopiridol in High-Risk Chronic Lymphocytic Leukemia*. Great Lakes Drug Metabolism Discussion Group Annual Meeting, Michigan, 2012.
 48. Yao Jiang, Yonghua Ling, Kelsie Bernot, Shujun Liu, Jia Ji, Jiang Wang, Nick Zorko, Susan Whitman, Mengzi Zhang, Xiaojuan Yang, Robert Lee, William Blum, Alison Walker, Guido Marcucci, Michael A. Caligiuri, **Mitch A. Phelps**. *Pharmacokinetics and Pharmacodynamics of Bortezomib*. OSU Comprehensive Cancer Center Annual Meeting, March 2012.
 49. Jiang Wang, Lei He, Yao Jiang, Yonghua Ling, Robert Lee, Chenglong Li, Pui-Kai Li, Robert Baiocchi, **Mitch Phelps**. *Pharmacokinetics of a novel protein arginine methyltransferase 5 inhibitor in mice*. OSU Comprehensive Cancer Center Annual Meeting, March 2012.
 50. Lei He, John Grecula, Yonghua Ling, Xiaoxia Yang, Michael Enzerra, Jeffrey Cotrill, Mario Ammirati, Kari Kendra, Robert Cavaliere, Ewa Mrozek, Barbara McCracken-Bussa, Laura Mayer, Nina Mayr, Lai Wei, **Mitch Phelps**. *Pharmacokinetics of Bendamustine in Patients with Brain Metastases from Solid Tumors: Evaluation of Bendamustine Blood-Brain Barrier Penetration*. OSU Comprehensive Cancer Center Annual Meeting, March 2012.
 51. Lei He, John Grecula, Yonghua Ling, Xiaoxia Yang, Michael Enzerra, Jeffrey Cotrill, Mario Ammirati, Kari Kendra, Robert Cavaliere, Nina Mayr, Ewa Mrozek, John McGregor, Thomas Olencki, Ennio Chiocca, James Elder, Mani Matharbootham, Tim Lautenschlaeger, Chimo Oluigbo, Barbara McCracken-Bussa, Laura Mayer, Lai Wei, **Mitch Phelps**. *Pharmacokinetics of Bendamustine, a Radiosensitizer in Treatment of Brain Metastases from Solid Tumors*. OSU College of Pharmacy Research Day, 2012.
 52. Ming J. Poi, Jeffrey Jones, Amy Ruppert, Jeffrey Cantrell, Jia Ji, Diana Chung, Niesha Griffith, **Mitch Phelps**. *Phase I/II Pharmacokinetic Study of Flavopiridol in Lymphomas*. OSU College of Pharmacy Research Day, 2012.
 53. Ming J. Poi, Wolfgang Sadee, Steve Devine, Jiang Wang, Elizabeth Marek, Niesha Griffith,

- Ali McBride, Jigar Trivedi, Julianna Roddy, Danxin Wang, Hong Zhu, **Mitch Phelps**. *A Prospective Double-Blind, Observational Clinical Study of the Association between Tacrolimus Exposure and CYP3A4, CYP3A5 Genotypes in Adult Hematopoietic Stem Cell Transplant Recipients*. OSU College of Pharmacy Research Day, 2012.
54. Kami Maddocks, Erin K. Hertlein, Joseph M. Flynn, Leslie A. Andritsos, Amy J. Wagner, Timothy L. Chen, **Mitch A. Phelps**, Michael R. Grever, Amy J. Johnson, John C. Byrd, Jeffrey A. Jones. *A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)*. *Blood*. Nov 2012, 120(21).
55. Jiang Y, Wang J, Walker A, Li X, Drake A, Schaaf L, Byrd J, Marcucci G, Grever M, Blum W, **Phelps M**. *Lenalidomide pharmacokinetics in combination with idarubicin and cytarabine in patients with acute myeloid leukemia*. *Clinical Pharmacology and Therapeutics*. Feb 2013, 93(1):S66-S67.
56. Ming J. Poi, Jigar Trivedi, Ali McBride, Julianna Roddy, Ee Poi, Jiang Wang, Danxin Wang, Hong Zhu, Elizabeth Marek, Shamalatha D. Kolli, Wolfgang Sadee, Steve Devine, Niesha Griffith, **Mitch Phelps**. *A Prospective, double-blinded, observational clinical cohort study of the association between tacrolimus exposure and CYP3A4, CYP3A5 genotypes in adult hematopoietic stem cell transplant recipients*. BMT Tandem Meetings, Salt Lake City, February 2013.
57. Yao Jiang, Jiang Wang, Alison Walker, Xiaobai Li, Amy Drake, Larry J. Schaaf, John C. Byrd, Guido Marcucci, Michael R. Grever, William Blum, **Mitch A. Phelps**. *Lenalidomide pharmacokinetics in combination with idarubicin and cytarabine in patients with acute myeloid leukemia*. ASCPT Annual Meeting, Indianapolis, March 2013.
58. Yuan Zhao, Tracy Parrott, Mary Syto, Francis J. Burrows, Robert Mansfield, **Mitch A. Phelps**. *Population Pharmacokinetic Modeling and Simulation of TG02 Citrate from Phase I Clinical Trial on Acute Myeloid Leukemia and Multiple Myeloma Patients*. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Indianapolis, March 2013.
59. Jack C. Yalowich, Anna Skwarska, Andrew J. Rabovsky, Yuan Zhao, **Mitch A. Phelps**, Billy W. Day, Ragu Kanagasabai. *Myeloperoxidase as a determinant for activity of etoposide (VP-16) and other phenolic and non-phenolic anticancer agents: implications for drug-induced leukemogenesis*. AACR Annual Meeting, Washington DC, April 2013.
60. Darlene M. Rozewski, Xiaoxia Yang, Yonghua Ling, Yao Jiang, Yue Gao, Amy J. Johnson, Kami Maddocks, Larry J. Schaaf, John C. Byrd, Kristie A. Blum, **Mitch A. Phelps**. *Pharmacokinetics of Combined Lenalidomide and Flavopiridol in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia*. OSU Comprehensive Cancer Center Annual Meeting, Columbus, OH, April 2013.
61. Yue Gao, Xiaobai Li, Junan Li, Kriss Petrovskis, Ming Poi, Jiang Wang, Misty Lamprecht, Megan Jukich, William Falk, Larry Schaaf, Craig Hofmeister, **Mitch A. Phelps**. *Optimizing sampling times for melphalan in phase II patients with multiple myeloma using population PK modeling*. OSU Comprehensive Cancer Center Annual Meeting, Columbus, OH, April 2013.
62. E Mrozek, M Lustberg, R Wesolowski, R Layman, Y Ling, L Schaaf, **M Phelps**, M Grever, CL Shapiro. *A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC)*. American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 31-June 4, 2013.
63. Jennifer Ann Woyach, Joseph M. Flynn, Jeffrey Alan Jones, Leslie A. Andritsos, Margaret Lucas, Weihong Chase, Ying Yang, David M. Lucas, Ellen Sass, Sharon Waymer, Yonghua Ling, Yao Jiang, **Mitch A. Phelps**, John C. Byrd. *Results of a phase I trial of the proteasome*

- inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL)*. American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 31-June 4, 2013.
64. R Mani, Y Mao, FW Frizzera, C Chiang, J Wang, Y Zhao, Y Wu, B Yu, X Mo, S Baskar, C Rader, **MA Phelps**, RJ Lee, CS Chen, LJ Lee, JC Byrd, N Muthusamy. *Tumor Antigen ROR1 Targeted Delivery of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model of Chronic Lymphocytic Leukemia*. American Society of Hematology Annual Meeting, New Orleans, LA, 2013.
65. J Wang, K Kasai, F Liu, S Kerr, H Nakashima, EA Chiocca, **MA Phelps**. *Plasma pharmacokinetics of cyclophosphamide, irinotecan and their active metabolites in mice with intracranial MGH2.1, an oncolytic virus expressing drug-activating enzymes*. American Association of Pharmaceutical Scientists Annual Meeting, San Antonio, TX, 2013.
66. DM Rozewski, YK Cho, TA Mace, L He, EB Schwartz, Y Ling, MA Bill, C London, J Lin, C Li, JR Fuchs*, GB Lesinski*, **MA Phelps**. *Comprehensive pharmacokinetic-pharmacodynamic modeling to optimize FLLL100P-induced inhibition of pSTAT3 in pancreatic cancer*. Great Lakes Drug Metabolism Discussion Group Meeting, Indianapolis, IN, 2014.
67. YK Cho, J Wang, Y Gao, J Li, M Lamprecht, M Jukich, LJ Schaaf, M Poi, CC Hofmeister, **MA Phelps**. *Pharmacokinetics and pharmacodynamics of high dose melphalan in multiple myeloma patients undergoing autologous stem cell transplant*. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, 2014.
68. Y Gao, J Li, J Wang, M Poi, X Li, M Lamprecht, M Jukich, K Petrovskis, D Jarjoura, W Falk, LJ Schaaf, CC Hofmeister, **MA Phelps**. *Nonlinear mixed effects modeling and simulation for melphalan pharmacokinetic sampling scheme optimization in patients with multiple myeloma*. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, 2014.
69. Y Zhao, Y Ling, S Kolli, M Poi, LJ Schaaf, AJ Johnson, JC Byrd, JA Jones, **MA Phelps**. *Dinaciclib and dinaciclib glucuronide pharmacokinetics in patients with chronic lymphocytic leukemia*. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, 2014.
70. S Haraldsdottir, F Janku, C Timmers, S Geyer, LJ Schaaf, J Sexton, J Thurmond, E Bertino, K Kendra, A Mortazavi, M Poi, **M Phelps**, MH Shah. *A phase I trial of Dabrafenib (BRAF inhibitor) and Pazopanib in BRAF mutated advanced malignancies*. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2014.
71. YK Cho, J Li, D Sborov, J Wang, Y Gao, M Lamprecht, M Poi, **MA Phelps**, CC Hofmeister. *Development of a predictive pharmacokinetic and pharmacodynamic model to personalize melphalan dosing in autologous transplant for patients with multiple myeloma*. American Society of Hematology Annual Meeting, San Francisco, CA, 2014.
72. D Sborov, M Lamprecht, K Tackett, DM Benson, YA Efebera, SM Devine, **M Phelps**, CC Hofmeister. *Randomized trial proves 2hr cryotherapy effectively reduces severe mucositis associated with high dose melphalan followed by stem cell rescue*. American Society of Hematology Annual Meeting, San Francisco, CA, 2014.
73. Yuan Zhao, Tracy Parrott, Mary Syto, Francis J. Burrows, Robert Mansfield, **Mitch A. Phelps**. *Population Pharmacokinetic Modeling and Simulation to Design New TG02 Dose Regimens for Evaluation in a Phase 1 Study in Leukemia Patients*. Annual Pharmaceutics Graduate Student Research Meeting, University of Illinois, Chicago, IL, 2014.
74. Yuan Zhao, Tracy Parrott, Mary Syto, Francis J. Burrows, Robert Mansfield, **Mitch A. Phelps**. *Dose Regimen Design for Phase 1 Evaluation of the Oral Multi-Kinase Inhibitor, TG02*. Oral presentation. American Association of Pharmaceutical Scientists Annual

- Meeting, San Diego, CA, 2014.
75. Yao Jiang, Hongyan Wang, Jiang Wang, Yonghua Ling, Alison R. Walker, Amy Drake, Larry J. Schaaf, John C. Byrd, Michael R. Grever, Guido Marcucci, William G. Blum, **Mitch A. Phelps**. *Pharmacokinetics and Pharmacodynamics of Lenalidomide in a Phase I Dose Escalation Study in Patients with Acute Myeloid Leukemia*. American Association of Pharmaceutical Scientists Annual Meeting, San Diego, CA, 2014.
 76. Yu Kyoung Cho, Junan Li, Jiang Wang, Yue Gao, Douglas Sborov, Misty Lamprecht, Megan Jukich, William Falk, Larry J. Schaaf, Ming Poi, Craig C. Hofmeister, **Mitch A. Phelps**. *Pharmacokinetic and Pharmacodynamic Modeling for Personalizing Melphalan Dosing in Multiple Myeloma Patients Receiving Autologous Transplant*. American Association of Pharmaceutical Scientists Annual Meeting, Orlando, FL, 2015.
 77. Peter Amaya, Eric Plencner, Ola Elgamal, Dhruvit Sutaria, **Mitch Phelps**, Thomas Schmittgen, Jeffrey Chalmers. *Microcarrier Culture Enhances Release of Therapeutic miRNA in Extracellular Vesicles by HEK293T Cells*. Biomedical Engineering Society Annual Meeting, Tampa, FL, 2015.
 78. Jinmai Jiang, Ola A. Elgamal, Dhruvit Sutaria, **Mitch A. Phelps**, Thomas D. Schmittgen. *Small RNA sequencing of HEK293T cells engineered to produce extracellular vesicles containing therapeutic microRNAs reveals preferential loading via Exo motifs*. Extracellular RNA Working Group Meeting, Bethesda, MD, October 2015.
 79. Joseph Markowitz, Jiang Wang, Zachary C. VanGundy, Jia You, Owen Branson, Vedat Yildiz, Lianbo Yu, Tracey L. Papenfuss, Michael Freitas, **Mitch Phelps**, William E. Carson, III. *Nitric oxide derived from myeloid derived suppressor cells inhibits antigen presentation form DCs to CD4+ T cells*. Florida Asthma, Allergy and Immunology Society Annual Meeting, Orlando, FL, 2015.
 80. John C. Grecula, Ashley Sekhon, Robert Cavaliere, Kari Kendra, Meng Welliver, John McGregor, **Mitch Phelps**, Lai Wei, Ewa Mrozek, Thomas Olencki, Julie Thelen, Daniel Prevedello, William Thoman, Mario Ammirati. *Phase I Study of Bendamustine (BD) and Fractionated Stereotactic Radiotherapy (FSRT) of Patients with 1-4 Brain Metastases from Solid Malignancies*. National Comprehensive Cancer Network Annual Conference, Orlando, FL, 2016.
 81. Yu Kyoung Cho, Douglas Sborov, Junan Li, Jiang Wang, Yue Gao, Misty Lamprecht, Megan Jukich, William Falk, Larry J. Schaaf, Ming Poi, Craig C. Hofmeister, **Mitch A. Phelps**. *Personalized melphalan therapy for autologous stem cell transplant: G-CSF regimen significantly influences duration of neutropenia*. American Society of Clinical Pharmacology and Therapeutics Annual Meeting, San Diego, CA, 2016.
 82. Hugo Valencia, Herbert Newton, Erinn M. Hade, Douglas W. Sborov, Robert Cavaliere, Ming Poi, **Mitch A. Phelps**, Christopher C. Coss, Jiang Wang, Soun Khountham, J. Paul Monk, Thomas E. Olencki, Charles L. Shapiro, Richard Piekarz, Craig C. Hofmeister, Michael R. Grever, D. Bradley Welling, Amir Mortazavi. *A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors*. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2016.
 83. **Mitch A. Phelps**. *Racial, Ethnic, and Gender Considerations in Cancer Drug Development: A Pharmacologist's Perspective*. Presenter and panelist. Accelerating Anticancer Agent Development and Validation Workshop, Bethesda, MD, May 2016.
 84. Francesca Cottini, Douglas W. Sborov, Yu Kyoung Cho, Misty Lamprecht, Karen Tackett, Junan Li, Steven Devine, Ming Poi, **Mitch A. Phelps**, Craig C. Hofmeister. *G-CSF Starting Day +1 After Autologous Transplant is Safer than Day +5 or Day +7 in Patients with Multiple Myeloma*. American Society of Hematology Annual Meeting, Atlanta, GA, 2016.

85. Xiaohua Zhu, Steven Pomeroy, Mohamed Badawi, Dhruvit Sutaria, Zhiliang Xie, Alice Baek, Jinmai Jiang, Krista LaPerle, Xiaokui Mo, Thomas, Schmittgen, **Mitch Phelps**. *Comprehensive toxicity and immunogenicity studies reveal no observable effects in immune competent mice dosed 3 weeks with exosomes derived from HEK 293T cells*. Extracellular RNA Consortium Meeting, Bethesda, MD, November 2016.
86. **Mitch Phelps**. *Lack of toxicity and immunogenicity in mice following 3-week dosing of engineered exosomes derived from HEK293T cells*. Extracellular RNA Consortium Meeting, Bethesda, MD, November 2016.
87. **Mitch Phelps**. *Towards an individualized melphalan dose in multiple myeloma patients undergoing stem cell transplant*. Erasmus University Medical Center, Laboratory of Translational Pharmacology, Rotterdam, Netherlands, January 2017.
88. **Mitch Phelps**. *Individualizing high dose melphalan therapy in multiple myeloma patients undergoing stem cell transplant*. Johns Hopkins University, Grand Rounds, Department of Medicine, Division of Clinical Pharmacology, March 2017.
89. Mohamed Badawi, JH Kim, Dhruvitkumar Sutaria, Ryan Reyes, Nissar Wani, T Motiwala, S Jacob, **M Phelps**, T Schmittgen. *CD44 positive and sorafenib resistant hepatocellular carcinomas respond to THE ATP-competitive mTOR inhibitor INK128*. American Association for Cancer Research Annual Meeting, Washington, DC, 2017.
90. Peter Amaya, **Mitch Phelps**, Tom Schmittgen, Jeffrey Chalmers. *Novel clone selection technique reveals heterogeneity among HEK293T cells engineered to produce therapeutic extracellular vesicles*. American Chemical Society Annual Meeting, San Francisco, CA, 2017.
91. **Mitch Phelps**. *The Clinical role of Transporters in Resistance: IMiDs as Case Examples*. Grand Rounds, Winship Cancer Institute, August 23, 2017.
92. **Mitch Phelps**. *MicroRNA Loaded Vesicles for Cancer Therapy*. Extracellular RNA Communication Consortium Meeting, Bethesda, MD, April 2018.
93. Nasser Nassiri Koopaei, Steven Pomeroy, **Mitch A. Phelps**, Thomas D. Schmittgen. *Pilot scale and GMP compliant production in stirred tank bioreactor and purification process of wild-type and engineered extracellular vesicles by TFF*. Extracellular RNA Consortium Meeting, Bethesda, MD, April 26, 2018.
94. Mohamed Badawi, Jinmai Jiang, Steve Pomeroy, Xiaohua Zhu, Thomas D. Schmittgen, **Mitch A. Phelps**, Mohamed Badawi. *Pharmacokinetics and hepatic tumor distribution of cholesterol-anti-miR-221 loaded EVs; important considerations for RT-qPCR assay validation in therapeutic EV studies*. Extracellular RNA Consortium Meeting, Bethesda, MD, April 27, 2018.
95. SG Liva, A Mortazavi, K Dittmar, AR Walker, CC Hofmeister, **MA Phelps**, CC Coss. *AR-42 pharmacokinetics: estimated versus measured patient body composition*. American Association of Pharmaceutical Scientists Annual Meeting, Washington, DC, November 2018.
96. Donald J. Irby, Yu Kyoung Cho, Mohamed Badawi, Anees Dauki, Craig C. Hofmeister, Diane R. Mould, **Mitch A. Phelps**. *Modeling of Neutropenia in the Setting of Autologous Stem Cell Transplant with Single, High Dose Chemotherapy and G-CSF*. American Conference on Pharmacometrics Annual Meeting, San Diego, CA, October 2018.
97. Mohamed Badawi, Jinmai Jiang, Steve Pomeroy, Anees Dauki, Xiaohua Zhu, Dhruvitkumar Sutaria, Thomas D. Schmittgen, **Mitch Phelps**. *Pharmacokinetic Evaluation and Biodistribution of Anti-mir-221 Loaded Exosomes in a Hepatocellular Carcinoma Orthotopic Mouse Model*. American Association of Pharmaceutical Scientists Annual Meeting, Washington, DC, November 2018.
98. Mohamed Badawi, Alison Walker, Alice Mims, Sumithira Vasu, William Blum, Rebecca

- Klisovic, Bhavana Bhatnagar, **Mitch Phelps**. *Pharmacokinetics of Selinexor in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia: A Phase I Trial*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Washington, DC, March 2019.
99. Min Chen, Yao Jiang, Darlene Bystry, Hanna Radomska, Brenna Weadick, Rajgopal Govindarajan, **Mitch Phelps**. *The Potential Role of Drug Transporters in Resistance to Immunomodulatory Drugs (IMiDs) Therapy*. Great Lakes Drug Metabolism and Disposition Group Meeting, Ann Arbor, MI, May 2019.
100. Timothy Helms, Jennifer Thomas-Ahner, Leon Xie, Moray Campbell, **Mitch Phelps**, Steven Clinton, Christopher Coss. *Preventive Anti-androgen Interventions Inhibit Tumor Initiation in a Diethylnitrosamine-Induced, Rodent Model of Hepatocellular Carcinogenesis*. Society for Toxicologic Pathology Annual Symposium, Raleigh, NC, June 2019.
101. Swagata Goswami, Chi-Ling Chiang, Kevan Zapolnik, Rajeswaran Mani, Zhiliang Xie, Xiaokui Mo, James L. Lee, Sivasubramanian Baskar, Christoph Rader, John C. Byrd, **Mitch Phelps**, Bhavana Bhatnagar, Natarajan Muthusamy. *ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19) translocated B-ALL*. American Society of Hematology Annual Meeting, Orlando, FL, December 2019.
102. **Mitch Phelps**. Important Considerations for Development of Extracellular Vesicles as Oligonucleotide Drug Carriers. Pharmscience Research and Development, Los Angeles, CA, February 2020.
103. Donald Irby, Francesca Cottini, Erinn Hade, Craig C. Hofmeister, **Mitch Phelps**. *Modeling Thrombocytopenia as a Predictor of Outcomes Following Single, High Dose Melphalan and Stem Cell Transplant in Multiple Myeloma*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Houston, TX, March 2020. (cancelled due to COVID-19)